Methods for Changing Body Composition
By administering GDF8 and activin A inhibitors, the method effectively reduces fat mass and increases muscle volume, addressing obesity-related issues and muscle loss, with minimal weight changes.
Patent Information
- Application Number
- JP2020545510
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-03-01
- Filing Date
- 2019-03-01
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2039-03-01
AI Technical Summary
Obesity is a global health issue characterized by chronic low-grade inflammation and excessive fat mass, leading to various serious conditions, and there is a need for effective treatments that reduce fat mass and increase muscle volume without significant weight changes.
A method involving the administration of GDF8 inhibitors and activin A inhibitors to subjects, which can include antibodies or antigen-binding fragments, to specifically target and inhibit the biological functions of these proteins, thereby reducing fat mass and increasing muscle volume.
The method effectively decreases fat mass and increases muscle volume in subjects, with minimal changes in total body weight, addressing conditions associated with excessive fat mass and muscle loss.
Smart Images

Figure 0007579706000018 
Figure 0007579706000019 
Figure 0007579706000020
Abstract
Description
[Technical field]
[0001] This application was filed as a PCT international patent application on March 1, 2019, and claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 637,017, filed March 1, 2018, the disclosure of which is hereby incorporated by reference in its entirety.
[0002] Sequence Listing This application contains a Sequence Listing in electronic format entitled "Sequence-Listing-40848-091WOU1", created on March 1, 2019, and having a size of 288 kilobytes (KB) (295,202 bytes). The contents of the txt file "Sequence-Listing-40848-091USU1" are incorporated herein by reference.
[0003] FIELD OF THEINVENTION The present invention relates to compositions and methods for modifying body composition in a subject. The compositions and methods also reduce fat mass in a subject. The compositions and methods also increase muscle mass and / or lean body mass in a subject. More specifically, the present invention relates to compositions comprising GDF8 inhibitors and activin A inhibitors, and the use of such compositions for treating diseases and disorders characterized by increased fat mass, and / or decreased muscle mass or decreased lean body mass. [Background technology]
[0004] Growth differentiation factor-8 (GDF8, also known as myostatin) is a secreted ligand that belongs to the transforming growth factor-β (TGF-β) superfamily of growth factors. GDF8 plays a central role in the development and maintenance of skeletal muscle, acting as a negative regulator of myogenesis and skeletal muscle mass. Myostatin mutations (including knockouts) lead to a phenotype that is primarily increased muscle mass, but may also consist of muscling (more muscle fibers), variants in myofiber composition (larger cross-sectional area of muscle fibers), and increased protein / DNA ratio.
[0005] Antibodies to GDF8 and methods of treatment are disclosed, for example, in U.S. Patent No. 6,233,663. Anti-GDF8 antibodies are also mentioned, for example, in U.S. Patent No. 6,233,663; ... and U.S. Patent No. 6,233,663;
[0006] Activins belong to the transforming growth factor-beta (TGF-β) superfamily and exert a wide range of biological effects in cell proliferation, differentiation, metabolism, homeostasis and apoptosis, as well as immune response and tissue repair. Activin A is a disulfide-linked homodimer (two beta-A chains) that binds to and activates heteromeric complexes of type I (Act RI-A and Act RI-B) and type II (Act RII-A and Act RII-B) serine-threonine kinase receptors.
[0007] Antibodies to activin A and their uses are disclosed, for example, in US Pat. No. 5,399,623; US Pat. No. 5,499,633; and US Pat. No. 5,523,361.
[0008] Compositions comprising anti-GDF8 and anti-activin A antibodies and methods of treatment are disclosed, for example, in US Pat. No. 5,399,633. [Prior art documents] [Patent documents]
[0009] [Patent Document 1] US8,840,894 [Patent Document 2] U.S. Patent No. 6,096,506 [Patent Document 3] U.S. Patent No. 7,320,789 [Patent Document 4] U.S. Patent No. 7,261,893 [Patent Document 5] U.S. Patent No. 7,807,159 [Patent Document 6] U.S. Patent No. 7,888,486 [Patent Document 7] U.S. Patent No. 7,635,760 [Patent Document 8] U.S. Patent No. 7,632,499 [Patent Document 9] US Patent Application Publication No. 2006 / 0263354 [Patent Document 10] US Patent Application Publication No. 2007 / 0178095 [Patent Document 11] US Patent Application Publication No. 2008 / 0299126 [Patent Document 12] US Patent Application Publication No. 2010 / 0166764 [Patent Document 13] US Patent Application Publication No. 2009 / 0148436 [Patent Document 14] International Patent Application Publication No. WO2004 / 037861 [Patent Document 15] International Patent Application Publication No. WO2007 / 047112 [Patent Document 16] International Patent Application Publication No. WO2010 / 070094 [Patent Document 17] US8,309,082 [Patent Document 18] US9,718,881 [Patent Document 19] International Patent Application Publication No. WO2008 / 031061 [Patent Document 20] US8,871,209 [Non-patent literature]
[0010] [Non-Patent Document 1] Britton JACC 2013 62;921 pages [Non-Patent Document 2] Atherosclerosis 2012 Summary of the Invention [Problem to be solved by the invention]
[0011] Obesity is a global problem for more than one-third of the world's population. In the United States, the average obesity rate is over 20%. The cost of obesity-related diseases is enormous, totaling $190.2 billion, approximately 21% of the annual medical expenditure in the United States. Obesity is a widespread disease characterized by chronic low-grade inflammation associated with dysfunctional (elevated) fat mass. In Framingham Heart Study participants, abdominal adiposity was associated with incident cardiovascular disease (CVD) after adjusting for clinical risk factors and overall adiposity. (2010) Abdominal visceral fat accumulation was positively associated with the progression of coronary noncalcified plaque. (2010) There remains a need for therapies that reduce total and / or android fat mass in subjects, as high fat mass is associated with serious conditions such as congestive heart failure, hypertension / hypertension, pulmonary embolism, osteoarthritis, lymphedema, gastroesophageal reflux disease, chronic renal failure, cancer, fatty liver disease, and even depression. [Means for solving the problem]
[0012] In one aspect, the present invention is directed to a method for altering body composition, i.e., increasing muscle mass and decreasing fat mass, in a subject, comprising administering to the subject a first composition comprising an effective amount of a GDF8 inhibitor and a second composition comprising an effective amount of an activin A inhibitor. In another aspect, the present invention is directed to a method for inducing a decrease in fat mass in a subject, comprising administering to the subject an effective amount of a composition comprising a GDF8 inhibitor and an activin A inhibitor.
[0013] In another embodiment, the present invention is directed to a method for treating a disease or disorder characterized by or associated with increased fat mass, comprising administering to a subject in need thereof a first composition comprising an effective amount of a GDF8 inhibitor and a second composition comprising an effective amount of an activin A inhibitor. In another embodiment, the present invention is directed to a method for treating a disease or disorder characterized by or associated with increased fat mass, comprising administering to a subject in need thereof an effective amount of a composition comprising a GDF8 inhibitor and an activin A inhibitor. In one embodiment, the present invention is directed to a method for modifying body composition in a subject, i.e., for increasing muscle mass and decreasing fat mass, comprising administering to a subject an effective amount of a GDF8 inhibitor and an effective amount of an activin A inhibitor, with no significant change in total body weight. Thus, in one embodiment of the present invention, a subject administered an effective amount of a GDF8 inhibitor and an effective amount of an activin A inhibitor will experience an increase in muscle mass along with a decrease in fat mass, resulting in minimal and / or no significant change in total body weight.
[0014] In one embodiment, the present invention is directed to the use of a GDF8 inhibitor and / or an activin A inhibitor in the preparation of a medicament for achieving a reduction in fat mass in a subject. In another embodiment, the present invention is directed to the use of a GDF8 inhibitor and / or an activin A inhibitor in the preparation of a medicament for treating a disease or disorder associated with increased fat mass in a subject.
[0015] In some embodiments, a GDF8 inhibitor is provided for use in a method for treating a disease or disorder characterized by increased fat mass, the method comprising administering to a subject a GDF8 inhibitor and an activin A inhibitor.
[0016] In some embodiments, an activin A inhibitor is provided for use in a method for treating a disease or disorder characterized by increased fat mass, the method comprising administering to a subject an activin A inhibitor and a GDF8 inhibitor.
[0017] In some embodiments, a non-therapeutic method for reducing fat mass in a subject is provided, the method comprising administering to the subject an activin A inhibitor and a GDF8 inhibitor.
[0018] In one embodiment of the method of the present invention, the effective amount of a GDF8 inhibitor comprises a dosage regimen selected from the group consisting of at least 0.1 mg / kg to about 10 gm / kg, 1 mg / kg to about 1 gm / kg, and 10 mg / kg to 100 mg / kg. In a further embodiment of the method of the present invention, the effective amount of a GDF8 inhibitor comprises a dosage regimen selected from the group consisting of a single dose of about 0.01 to about 20 mg / kg body weight, about 0.1 to about 10 mg / kg body weight, and about 0.1 to about 5 mg / kg body weight.
[0019] In another embodiment of the method of the present invention, the effective amount of the activin A inhibitor comprises a dosage regimen selected from the group consisting of at least 0.1 mg / kg to about 10 gm / kg, 1 mg / kg to about 1 gm / kg, and 10 mg / kg to 100 mg / kg. In a further embodiment of the method of the present invention, the effective amount of the activin A inhibitor comprises a dosage regimen selected from the group consisting of about 0.01 to about 20 mg / kg body weight, about 0.1 to about 10 mg / kg body weight, and a single dose of about 0.1 to about 5 mg / kg body weight.
[0020] In one embodiment of the method of the present invention, the effective amount of the GDF8 inhibitor is 6 mg / kg body weight and the effective amount of the activin A inhibitor is 3 mg / kg body weight. In one embodiment of the method of the present invention, the effective amount of the GDF8 inhibitor is 6 mg / kg body weight and the effective amount of the activin A inhibitor is 10 mg / kg body weight.
[0021] In one embodiment of the method of the present invention, the first composition is formulated for intravenous, subcutaneous or oral administration.In another embodiment of the method of the present invention, the second composition is formulated for intravenous, subcutaneous or oral administration.In certain embodiments of the method of the present invention, the first and second compositions are administered to the subject simultaneously or sequentially.
[0022] In one embodiment of the method of the present invention, the first and second compositions are combined into a third composition prior to administration, hi a further embodiment, the third composition is formulated for intravenous, subcutaneous or oral administration.
[0023] In one embodiment, the method further comprises measuring total fat mass in the subject prior to administration, hi another embodiment, the method further comprises measuring total fat mass in the subject after administration and administering the first and second compositions until the subject achieves a reduction in total fat mass of at least 2%-8%, 2.5%-6%, 3%-4%, or at least 2.0%, at least 2.5%, at least 3.0%, or at least 3.5% or more.
[0024] In one embodiment, the method further comprises measuring android fat mass in the subject prior to administration, hi another embodiment, the method further comprises measuring android fat mass in the subject after administration and administering the first and second compositions until the subject achieves a reduction in android fat mass of at least 2%-8%, 2.5%-6%, 3%-4%, or at least 2.0%, at least 2.5%, at least 3.0%, or at least 3.5% or more.
[0025] In one embodiment, the method further comprises measuring subcutaneous adipose tissue volume in the subject prior to administration. In another embodiment, the method further comprises measuring subcutaneous adipose tissue volume in the subject after administration and administering the first and second compositions until the subject achieves a reduction in android fat mass of at least 2%-8%, 2.5%-6%, 3%-4%, or at least 2.0%, at least 2.5%, at least 3.0%, or at least 3.5% or more.
[0026] In some embodiments, a method is provided comprising administering to a subject in need thereof an effective amount of a GDF8 inhibitor and an effective amount of an activin A inhibitor, wherein the GDF8 inhibitor and the activin A inhibitor are co-administered within 48 hours or less, 24 hours or less, 12 hours or less, 6 hours or less, 3 hours or less, or 1 hour or less.
[0027] In some embodiments, a method is provided comprising administering to a subject in need thereof an effective amount of a GDF8 inhibitor and an effective amount of an activin A inhibitor, wherein the subject exhibits a decrease in total fat mass, android fat mass and / or subcutaneous adipose tissue volume.
[0028] In some embodiments, a method is provided comprising administering to a subject in need thereof an effective amount of a GDF8 inhibitor and an effective amount of an activin A inhibitor, wherein the subject exhibits a reduction in total fat mass, android fat mass and / or subcutaneous adipose tissue volume 4 weeks or more or 8 weeks or more after the administration.
[0029] In some embodiments, a method is provided comprising administering to a subject in need thereof an effective amount of a GDF8 inhibitor and an effective amount of an activin A inhibitor, wherein the subject exhibits a reduction in total fat mass, android fat mass and / or subcutaneous adipose tissue volume, and wherein the subject does not exhibit reduced thigh intramuscular adipose tissue volume.
[0030] In some embodiments, a method is provided comprising administering to a subject in need thereof an effective amount of a GDF8 inhibitor and an effective amount of an activin A inhibitor, wherein the subject exhibits a reduction in total fat mass, android fat mass and / or subcutaneous adipose tissue volume, and wherein the subject does not exhibit reduced thigh intramuscular adipose tissue volume 4 weeks or more or 8 weeks or more after administration.
[0031] In some embodiments, a kit is provided that includes a first container containing an effective amount of a GDF8 inhibitor and a second container containing an effective amount of a specific activin A inhibitor.
[0032] In some embodiments, the GDF8 inhibitor is an isolated antibody or antigen-binding fragment thereof that specifically binds to GDF8.
[0033] In one embodiment of the method of the invention, the GDF8 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds to GDF8. In another embodiment, the antibody or antigen-binding fragment that specifically binds to GDF8 comprises a heavy chain complementarity determining region (HCDR) of the heavy chain variable region (HCVR) that comprises SEQ ID NO: 360, and a light chain complementarity determining region (LCDR) of the light chain variable region (LCVR) that comprises SEQ ID NO: 368. In yet another embodiment, the antibody or antigen-binding fragment that specifically binds to GDF8 comprises three HCDRs that comprise SEQ ID NO: 362, SEQ ID NO: 364, and SEQ ID NO: 366, and three LCDRs that comprise SEQ ID NO: 370, SEQ ID NO: 372, and SEQ ID NO: 374.
[0034] In some embodiments, the activin A inhibitor is an isolated antibody or antigen-binding fragment thereof that specifically binds to activin A.
[0035] In one embodiment of the method of the invention, the activin A inhibitor is an antibody or antigen-binding fragment thereof that specifically binds to activin A. In another embodiment, the antibody or antigen-binding fragment that specifically binds to activin A comprises a heavy chain complementarity determining region (HCDR) of the heavy chain variable region (HCVR) that comprises SEQ ID NO: 553, and a light chain complementarity determining region (LCDR) of the light chain variable region (LCVR) that comprises SEQ ID NO: 537. In yet another embodiment, the antibody or antigen-binding fragment that specifically binds to activin A comprises three HCDRs that comprise SEQ ID NO: 555, SEQ ID NO: 557, and SEQ ID NO: 559, and three LCDRs that comprise SEQ ID NO: 539, SEQ ID NO: 541, and SEQ ID NO: 543.
[0036] In one embodiment of the method of the present invention, the effective dose of the activin A inhibitor is selected from the group including between 100% and 200% of the effective dose of the GDF8 inhibitor, between 100% and 250% of the effective dose of the GDF8 inhibitor, between 100% and 300% of the effective dose of the GDF8 inhibitor, and between 100% and 400% by weight of the effective dose of the GDF8 inhibitor.
[0037] In another embodiment of the method of the present invention, the weight ratio of the effective dose of the activin A inhibitor to the effective dose of the GDF8 inhibitor is 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 3:1 to 1:3, or about 2:1 to 1:2. In another embodiment of the method of the present invention, the weight ratio of the effective dose of the activin A inhibitor is about 1.5 to 2.0 times greater by weight than the amount of the GDF8 inhibitor.
[0038] In one embodiment of the methods of the invention, the GDF8 inhibitor is a bispecific antibody or antigen-binding fragment thereof that specifically binds to GDF8 and also specifically binds to activin A. In another embodiment, the activin A inhibitor is a bispecific antibody or antigen-binding fragment thereof that specifically binds to activin A and also specifically binds to GDF8.
[0039] In one embodiment of the method of the present invention, the reduction in fat mass in the subject is a reduction in total fat mass measured by DXA (dual energy x-ray absorptiometry).In another embodiment of the method of the present invention, the reduction in fat mass in the subject is a reduction in android fat mass measured by DXA (dual energy x-ray absorptiometry).
[0040] In one embodiment of the method of the present invention, the reduction in fat mass in the subject is a reduction in subcutaneous adipose tissue volume as measured by MRI (Magnetic Resonance Imaging).
[0041] In one embodiment of the method of the present invention, the subject develops an increase in muscle volume. The muscle volume may be thigh muscle tissue volume, for example, measured by MRI. In some embodiments, the muscle volume may be thigh muscle tissue volume, for example, measured by MRI. In some embodiments, the thigh muscle volume may be thigh muscle tissue volume including intramuscular fat tissue and large blood vessels, or thigh muscle tissue volume excluding intramuscular fat tissue and large blood vessels, for example, measured by MRI.
[0042] In one embodiment of the method of the present invention, the subject develops an increase in total lean mass, which can be measured by DXA (dual x-ray absorptiometry).
[0043] In one embodiment of the method of the present invention, the subject develops an increase in appendicular lean body mass, which can be measured by DXA and calculated, for example, by the aLBM equation.
[0044] In one embodiment of the methods of the present invention, the subject undergoes a loss of total fat mass, for example as measured by DXA.
[0045] In one embodiment of the method of the present invention, the subject undergoes a loss of android fat mass, as measured, for example, by DXA.
[0046] In one embodiment of the methods of the present invention, the subject experiences a decrease in subcutaneous adipose tissue volume, for example as measured by DXA.
[0047] In one embodiment of the methods of the present invention, the subject experiences a reduction in the sum of the fat mass in the arms and legs, as measured, for example, by DXA.
[0048] In one embodiment of the invention, the subject does not exhibit a loss of thigh intramuscular adipose tissue volume, for example as measured by MRI.
[0049] In one embodiment of the invention, the subject does not exhibit a loss of total bone mineral density (BMD) mass, for example as measured by DXA.
[0050] In one embodiment of the invention, the subject does not exhibit a loss of total bone mineral content (BMC) mass, for example as measured by DXA.
[0051] In one embodiment of the invention, the subject exhibits an increase in total bone mineral content (BMC) mass, for example as measured by DXA.
[0052] In another embodiment of the methods of the present invention, the subject is free of a muscle wasting condition or disease.
[0053] In some embodiments, a kit is provided for use in altering body composition, reducing fat mass, increasing lean mass, or treating a disease or disorder characterized by or associated with increased fat mass, the kit comprising a first container comprising a composition comprising an effective amount of a GDF8 inhibitor, and a second container comprising a second composition comprising an effective amount of an activin A inhibitor.
[0054] In some embodiments, a GDF8 inhibitor is provided for use in the manufacture of a first composition for use as a pharmaceutical in a kit for altering body composition, reducing fat mass, increasing lean mass, or treating a disease or disorder characterized by or associated with increased fat mass, the kit further comprising a second composition comprising an activin A inhibitor.
[0055] In some embodiments, an activin A inhibitor is provided for use in the manufacture of a first composition for use as a pharmaceutical in a kit for altering body composition, reducing fat mass, increasing lean mass, or treating a disease or disorder characterized by or associated with increased fat mass, the kit further comprising a second composition comprising a GDF8 inhibitor.
[0056] In some embodiments, a GDF8 inhibitor is provided for use in the manufacture of a first composition for use in a kit for altering body composition, reducing fat mass, or increasing lean mass in a subject, the kit further comprising a second composition comprising an activin A inhibitor.
[0057] In some embodiments, an activin A inhibitor is provided for use in the manufacture of a first composition for use in a kit for altering body composition, reducing fat mass, or increasing lean mass in a subject, the kit further comprising a second composition comprising a GDF8 inhibitor.
[0058] In some embodiments, a first composition comprising a GDF8 inhibitor is provided for use in altering body composition, reducing fat mass, increasing lean mass, or treating a disease or disorder characterized by or associated with increased fat mass or decreased lean mass in a subject who has received a second composition comprising an activin A inhibitor.
[0059] In some embodiments, a first composition comprising an activin A inhibitor is provided for use in altering body composition, reducing fat mass, increasing lean mass, or treating a disease or disorder characterized by or associated with increased fat mass or decreased lean mass in a subject who has received a second composition comprising a GDF8 inhibitor.
[0060] In some embodiments, a first composition comprising a GDF8 inhibitor is provided for use in a method for altering body composition, reducing fat mass, increasing lean mass, or treating a disease or disorder characterized by or associated with increased fat mass or decreased lean mass, the method further comprising administering a second composition comprising an activin A inhibitor.
[0061] In some embodiments, a first composition comprising an activin A inhibitor is provided for use in a method for altering body composition, reducing fat mass, increasing lean mass, or treating a disease or disorder characterized by or associated with increased fat mass or decreased lean mass, the method further comprising administering a second composition comprising a GDF8 inhibitor.
[0062] In some embodiments, a composition comprising an activin A inhibitor and a GDF8 inhibitor is provided for use in the treatment or prevention of a disease or disorder characterized by or associated with altered body composition, loss of fat mass, increase in lean mass, increased fat mass or decreased lean mass.
[0063] Other embodiments of the present invention will become apparent from a review of the detailed description that follows. [Brief description of the drawings]
[0064] [Figure 1]FIG. 1 shows a bar graph depicting the results of a clinical study in sarcopenic patients aged 70 years or older receiving the anti-GDF8 antibody REGN1033 alone after 12 weeks as percent change from baseline in total lean mass in LS mean and SE compared to placebo. Patients receiving REGN1033 showed significantly increased total lean mass at 12 weeks in each of the three dosing regimens compared to placebo (n=65). Patients receiving 100mg anti-GDF8 antibody REGN1033 Q4W SC showed a difference of 1.66% total lean mass vs. placebo (n=62, P=0.0077). Patients receiving 300mg anti-GDF8 Q4W SC showed a difference of 1.78% total lean mass vs. placebo (n=64, P=0.0043). Patients receiving 300 mg Q2W SC demonstrated a difference of 2.29% total lean mass vs. placebo (n=59, P=0.0004). [Figure 2A] 2A shows Table 1 with ascending dose panel used in a study of 48 healthy postmenopausal women according to Example 2. A single intravenous dose of anti-GDF8 antibody REGN1033 and / or anti-activin A antibody REGN2477 was utilized. In the primary analysis, placebo and high dose combination groups were pooled across the panel, resulting in 12 subjects in placebo and 12 in the high dose combination, as shown in the boxed area in the table. [Figure 2B] 2B shows a bar graph depicting the percent change in thigh muscle volume (measured by MRI) at 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women. The anti-GDF8 (6 mg / kg), anti-GDF8 (6 mg / kg) + mid-dose anti-activin A (3 mg / kg), and anti-GDF8 (6 mg / kg) + high-dose anti-activin A (10 mg / kg) groups showed a significant increase in percent change in thigh muscle volume from placebo (*nominal p<0.5 vs. placebo, ****nominal p<0.0001 vs. placebo). [Figure 2C]FIG. 2C shows a bar graph depicting the percent change in total fat mass (measured by DXA) at 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women. Values indicate change from placebo. The anti-GDF8 (6 mg / kg) + high dose anti-activin A (10 mg / kg) group showed a significant decrease in percent change in total fat mass (*nominal p<0.05, vs. placebo). [Diagram 3] 3 shows a line graph depicting the LS mean (SE) percent change from baseline in thigh muscle volume by MRI at weeks 0, 4, and 8 after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women. At week 4 after a single IV dose, each of the anti-GDF8 (6 mg / kg), anti-GDF8 (6 mg / kg) + low dose anti-activin A (1 mg / kg), anti-GDF8 (6 mg / kg) + mid dose anti-activin A (3 mg / kg), and anti-GDF8 (6 mg / kg) + high dose anti-activin A (10 mg / kg) groups demonstrated a significant increase in thigh muscle volume (excluding intramuscular adipose tissue, as measured by MRI) percent change from placebo. At 8 weeks after a single IV dose, the anti-GDF8 (6 mg / kg) + mid-dose anti-activin A (3 mg / kg) and anti-GDF8 (6 mg / kg) + high-dose anti-activin A (10 mg / kg) groups demonstrated significant increases in thigh muscle volume % change from placebo (*nominal p<0.05, **nominal p<0.001). N values per group are shown in Figure 2A. [Figure 4]FIG. 4 shows a line graph depicting individual data of percent change (from baseline) in thigh muscle volume by MRI in healthy postmenopausal women at 0, 4 and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 as % change from baseline in placebo, anti-GDF8 (6 mg / kg), high dose anti-activin A (10 mg / kg), anti-GDF8 (6 mg / kg) + low dose anti-activin A (1 mg / kg), anti-GDF8 (6 mg / kg) + medium dose anti-activin A (3 mg / kg), and anti-GDF8 (6 mg / kg) + high dose anti-activin A (10 mg / kg) groups for multiple individuals. Increases in thigh muscle volume were consistently observed in individual subjects after treatment with the combination of REGN2477 + REGN1033. Within each treatment group, different lines represent different individuals. [Diagram 5] 5 shows a line graph depicting appendicular lean (body weight) mass (i.e., the sum of lean tissue in arms and legs) in healthy postmenopausal women at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 as % percent change LS (least squares) mean (SE) from baseline in six groups. N values per group are shown in FIG. 2A. After 4 and 8 weeks, each of the three combination dose groups, including anti-GDF8 (6 mg / kg) + low dose anti-activin A (1 mg / kg), anti-GDF8 (6 mg / kg) + mid dose anti-activin A (3 mg / kg), and anti-GDF8 (6 mg / kg) + high dose anti-activin A (10 mg / kg) groups, showed significantly increased % change LS mean difference in appendicular lean mass compared to placebo (*nominal p<0.05, **nominal p<0.001). N values per group are shown in Figure 2A. [Figure 6]FIG. 6 shows a line graph depicting the mean (SE=standard error) percent total fat mass (measured by DXA) change at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women in the placebo, anti-GDF8 (6 mg / kg), high-dose anti-activin A (10 mg / kg), anti-GDF8 (6 mg / kg) + low-dose anti-activin A (1 mg / kg), anti-GDF8 (6 mg / kg) + medium-dose anti-activin A (3 mg / kg), and anti-GDF8 (6 mg / kg) + high-dose anti-activin A (10 mg / kg) groups. N values per group are shown in FIG. 2A. The high dose group, (anti-GDF8 (6 mg / kg) + high dose anti-activin A (10 mg / kg), showed a significant reduction in total fat mass as percent change LS mean difference compared to placebo at weeks 4 and 8 (*nominal p<0.05). Blockade of both activin A and GDF8 resulted in a reduction in total fat mass as assessed by DXA. [Figure 7] FIG. 7 shows a line graph depicting the mean (SE) percent change in android fat mass at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women in six groups including placebo, anti-GDF8 (6 mg / kg), high dose (10 mg / kg) anti-activin A, anti-GDF8 (6 mg / kg) + low dose (1 mg / kg) anti-activin A, anti-GDF8 (6 mg / kg) + medium dose (3 mg / kg) anti-activin A, and anti-GDF8 (6 mg / kg) + high dose (10 mg / kg) anti-activin A groups. The high dose REGN1033 + REGN2477 group showed significantly reduced percent change LS mean difference in android fat mass by DXA at weeks 4 and 8 compared to placebo (*nominal p<0.05). N values per group are shown in Figure 2 A. Blockade of both activin A and GDF8 was also associated with a reduction in android fat mass as assessed by DXA. [Figure 8]FIG. 8 shows line graphs depicting the LS mean percent change and SE in thigh muscle volume (excluding intramuscular adipose tissue and large blood vessels) at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women in six groups including placebo, anti-GDF8 (6 mg / kg), high dose (10 mg / kg) anti-activin A, anti-GDF8 (6 mg / kg) + low dose (1 mg / kg) anti-activin A, anti-GDF8 (6 mg / kg) + medium dose (3 mg / kg) anti-activin A, and anti-GDF8 (6 mg / kg) + high dose (10 mg / kg) anti-activin A groups. N values per group are shown in FIG. 2A. Compared to placebo, the REGN2477+REGN1033 intermediate and high dose groups demonstrated significantly increased mean % change in thigh muscle volume at 4 and 8 weeks (*nominal p<0.05, **nominal p<0.001). [Figure 9] 9 shows line graphs depicting the LS mean percent change and SE in total lean mass at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women for six groups including placebo, anti-GDF8 (6 mg / kg), high dose (10 mg / kg) anti-activin A, anti-GDF8 (6 mg / kg) + low dose (1 mg / kg) anti-activin A, anti-GDF8 (6 mg / kg) + medium dose (3 mg / kg) anti-activin A, and anti-GDF8 (6 mg / kg) + high dose (10 mg / kg) anti-activin A groups. N values per group are shown in FIG. 2A. Compared to placebo, the REGN2477 + REGN1033 intermediate and high dose groups demonstrated significantly increased % change in total lean mass compared to placebo at weeks 4 and 8 (*nominal p<0.05). [Figure 10]10 shows a line graph depicting the LS mean percent change and SE in appendicular lean body mass in kg (calculated by the aLBM equation) at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women in six groups including placebo, anti-GDF8, high dose (10 mg / kg) anti-activin A, anti-GDF8+low dose (1 mg / kg) anti-activin A, anti-GDF8+mid dose (3 mg / kg) anti-activin A, and anti-GDF8+high dose (10 mg / kg) anti-activin A groups. N values per group are shown in FIG. 2A. REGN2477+REGN1033 treatment resulted in significantly increased % change in appendicular lean mass (kg) as calculated by the aLBM equation) in each of the low, mid and high dose groups at weeks 4 and 8 compared to placebo (*p<0.05, **p<0.001). [Figure 11] 11 shows a line graph depicting the LS mean percent change and SE in total fat mass in kg in healthy postmenopausal women at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in six groups including placebo, anti-GDF8 (6 mg / kg), high dose (10 mg / kg) anti-activin A, anti-GDF8 + low dose (1 mg / kg) anti-activin A, anti-GDF8 (6 mg / kg) + medium dose (3 mg / kg) anti-activin A, and anti-GDF8 (6 mg / kg) + high dose (10 mg / kg) anti-activin A groups. N values per group are shown in FIG. 2A. The high dose combination REGN2477+REGN1033 treatment group demonstrated a significantly reduced % total fat mass: -3.92% (high dose group) compared to placebo -0.65% at week 8 (*nominal p<0.05). [Figure 12]12 shows a line graph depicting the LS mean percent change and SE in thigh muscle volume (including intramuscular adipose tissue and large blood vessels) in cm3 at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women in six groups including placebo, anti-GDF8, high dose (10 mg / kg) anti-activin A, anti-GDF8+low dose (1 mg / kg) anti-activin A, anti-GDF8+mid dose (3 mg / kg) anti-activin A, and anti-GDF8+high dose (10 mg / kg) anti-activin A groups. N values per group are shown in FIG. 2A. The high and mid dose REGN2477+REGN1033 treatment groups demonstrated significantly increased % change in thigh muscle volume, including intramuscular adipose tissue and large blood vessels, in the mid and high dose treatment groups at weeks 4 and 8 compared to placebo (*nominal p<0.05, **nominal p<0.001). [Figure 13] 13 shows a line graph depicting the LS mean percent change and SE in appendicular lean mass (sum of arm and leg lean mass) in kg in healthy postmenopausal women at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in six groups including placebo, anti-GDF8, high dose (10 mg / kg) anti-activin A, anti-GDF8+low dose (1 mg / kg) anti-activin A, anti-GDF8+mid dose (3 mg / kg) anti-activin A, and anti-GDF8+high dose (10 mg / kg) anti-activin A groups. N values per group are shown in FIG. 2A. Appendicular lean mass was significantly increased as mean percent change from placebo in each of the REGN2477+REGN1033 low, medium and high dose treatment groups at weeks 4 and 8 (*nominal p<0.05, **nominal p<0.001). [Figure 14]FIG. 14 shows a line graph depicting the LS mean percent change and SE in android fat mass in kg at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women in six groups including placebo, anti-GDF8, high dose (10 mg / kg) anti-activin A, anti-GDF8+low dose (1 mg / kg) anti-activin A, anti-GDF8+mid dose (3 mg / kg) anti-activin A, and anti-GDF8+high dose (10 mg / kg) anti-activin A groups. N values per group are shown in FIG. 2A. The high dose REGN1033+REGN2477 group showed significantly reduced % change in android fat mass by DXA compared to placebo at weeks 4 and 8 (*nominal p<0.05). [Figure 15] FIG. 15 shows a line graph depicting the LS mean percent change and SE in thigh intramuscular adipose tissue volume in cm3 at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women in six groups including placebo, anti-GDF8, high dose (10 mg / kg) anti-activin A, anti-GDF8+low dose (1 mg / kg) anti-activin A, anti-GDF8+mid dose (3 mg / kg) anti-activin A, and anti-GDF8+high dose (10 mg / kg) anti-activin A groups. N values per group are shown in FIG. 2A. The high dose REGN1033+REGN2477 group showed increased thigh intramuscular adipose tissue volume as mean % change compared to placebo at week 8 (*nominal p<0.05). [Figure 16]FIG. 16 shows line graphs depicting the LS mean percent change and SE in the sum of intramuscular and perimuscular adipose tissue (IMAT) at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women in six groups including placebo, anti-GDF8, high dose (10 mg / kg) anti-activin A, anti-GDF8+low dose (1 mg / kg) anti-activin A, anti-GDF8+mid dose (3 mg / kg) anti-activin A, and anti-GDF8+high dose (10 mg / kg) anti-activin A groups. N values per group are shown in FIG. 2A. The combination REGN1033+REGN2477 treatment group did not have significantly different LS mean percent change and SE in the sum of intramuscular and perimuscular adipose tissue (IMAT) at 4 and 8 weeks from placebo. [Figure 17] FIG. 17 shows a line graph depicting the LS mean percent change and SE in subcutaneous adipose tissue volume in cm3 at 0, 4, and 8 weeks after a single IV dose of anti-activin A antibody REGN2477 and / or anti-GDF8 antibody REGN1033 in healthy postmenopausal women in six groups including placebo, anti-GDF8, high dose (10 mg / kg) anti-activin A, anti-GDF8+low dose (1 mg / kg) anti-activin A, anti-GDF8+mid dose (3 mg / kg) anti-activin A, and anti-GDF8+high dose (10 mg / kg) anti-activin A groups. N values per group are shown in FIG. 2A. REGN1033+REGN2477 low and mid dose treatment groups showed significantly reduced % change in subcutaneous adipose tissue volume compared to placebo at 8 weeks (*nominal p<0.05). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0065] Before describing the present invention, it should be understood that the present invention is not limited to the specific compositions, methods and experimental conditions described, since they may vary.It should also be understood that the terminology used herein is intended to describe specific embodiments only and is not intended to be limiting, since the scope of the present invention is limited only by the appended claims.Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs.
[0066] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a method" includes one or more methods and / or steps of the type described herein and / or that will become apparent to those skilled in the art upon reading this disclosure.
[0067] As used herein, the term "about" when used in reference to a specific recited numerical value means that the value may vary by 1% or less from the recited value. For example, as used herein, the expression "about 100" includes 99 and 101, as well as all values therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0068] Although any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred methods and materials are described herein. All publications mentioned herein are incorporated by reference in their entirety.
[0069] Antibodies and antigen-binding fragments of antibodies The term "antibody" is intended herein to refer to an immunoglobulin molecule comprising four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM). Each heavy chain comprises a heavy chain variable region (herein referred to as HCVR or V H The heavy chain constant region is made up of three domains: H 1. C H 2 and C H Each light chain comprises a light chain variable region (herein, LCVR or V L The light chain constant region comprises one domain (C L 1) is included. H and V L The regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with more conserved regions, termed framework regions (FRs). H and V L is composed of three CDRs and four FRs arranged in the following order from amino-terminus to carboxy-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the invention, the FRs of the antibody (or antigen-binding portion thereof) may be identical to human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.
[0070] Antibodies may be referred to herein according to the following nomenclature: an Fc prefix (e.g., "H1M", "H2aM", "H4H") followed by a numerical identifier (e.g., "10446") followed by a "P", "P2" or "N" suffix. Thus, according to this nomenclature, an antibody may be referred to herein as, for example, "H4H10446P2". The H1M, H2M and H4H prefixes in the antibody nomenclature used herein indicate the particular Fc region isotype of the antibody. For example, an "H2aM" antibody has a murine IgG2a Fc, while an "H4H" antibody has a human IgG4 Fc. As one of skill in the art will recognize, an antibody having a particular Fc isotype can be converted to an antibody having a different Fc isotype (e.g., an antibody having a murine IgG2a Fc can be converted to an antibody having a human IgG4, etc.), but in each case the variable domains (including the CDRs) will remain the same and the binding characteristics are expected to be the same or substantially similar regardless of the nature of the Fc domain.
[0071] The term "antibody" as used herein also includes antigen-binding fragments of a complete antibody molecule. The terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies can be obtained from complete antibody molecules using any suitable standard technique, such as, for example, proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and optionally constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage-antibody libraries), or can be synthesized. The DNA can be sequenced and manipulated chemically or by using molecular biology techniques, for example, to place one or more variable and / or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, and the like.
[0072] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues that mimic the hypervariable regions (e.g., isolated complementarity determining regions (CDRs) such as CDR3 peptides) of antibodies or constrained FR3-CDR3-FR4 peptides. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain deleted antibodies, chimeric antibodies, CDR grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs) and shark variable IgNAR domains, are also encompassed within the expression "antigen-binding fragments" herein.
[0073] An antigen-binding fragment of an antibody will typically contain at least one variable domain. The variable domain may be of any size or amino acid composition and will generally contain at least one CDR adjacent to or in frame with one or more framework sequences. L Domain-associated V H In an antigen-binding fragment having a domain, H and V L The domains can be positioned relative to each other in any suitable configuration. For example, the variable region may dimerize into a V H -V H , V H -V L or V L -V L Alternatively, the antigen-binding fragment of the antibody may contain a monomeric V H or V L It may contain domains.
[0074] In certain embodiments, an antigen-binding fragment of an antibody can contain at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found in an antigen-binding fragment of an antibody used in the present invention include: (i) a V H -C H 1;(ii)V H -C H 2;(iii)V H -C H 3;(iv)V H -C H 1-C H 2;(v)V H -C H 1-C H 2-C H 3;(vi)V H -C H 2-C H 3;(vii)V H -C L ;(viii)V L -C H 1;(ix)V L -CH 2;(x)V L -C H 3;(xi)V L -C H 1-C H 2;(xii)V L -C H 1-C H 2-C H 3;(xiii)V L -C H 2-C H 3; and (xiv) V L -C L In any configuration of the variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains can be directly linked to each other or can be linked by a complete or partial hinge or linker region. The hinge region can consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that provide a flexible or semi-flexible linkage between adjacent variable and / or constant domains in a single polypeptide molecule. Furthermore, antigen-binding fragments of antibodies used in the present invention can be linked to each other and / or to one or more monomeric V H Or V L The variable and constant domains may comprise homodimers or heterodimers (or other multimers) of any of the variable and constant domain configurations listed above non-covalently associated (e.g., by disulfide bond(s)) with the domain.
[0075] Full antibody molecules and antigen-binding fragments may be monospecific or multispecific (e.g., bispecific). Multispecific antibodies or antigen-binding fragments of antibodies typically contain at least two different variable domains, each capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multispecific antibody format can be adapted for use in the context of the antibodies or antigen-binding fragments described herein using routine techniques available in the art.
[0076] The antibodies used in the compositions and methods of the present invention can function through complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC). "Complement-dependent cytotoxicity" (CDC) refers to the lysis of antigen-expressing cells by the antibodies of the present invention in the presence of complement. "Antibody-dependent cell-mediated cytotoxicity" (ADCC) refers to a cell-mediated reaction in which non-specific cytotoxic cells expressing Fc receptors (FcRs) (e.g., natural killer (NK) cells, neutrophils and macrophages) recognize bound antibodies on the surface of target cells, thereby resulting in the lysis of the target cells. CDC and ADCC can be measured using assays well known and available in the art (see, e.g., U.S. Pat. Nos. 5,500,362 and 5,821,337 and Clynes et al., Proc. Natl. Acad. Sci. (USA) 95:652-656 (1998)).
[0077] The antibodies described herein can comprise or consist of human antibodies and / or recombinant human antibodies, or fragments thereof. The term "human antibody" as used herein includes antibodies with variable and constant regions derived from human germline immunoglobulin sequences. Nevertheless, human antibodies can contain amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced in vitro by random or site-specific mutagenesis, or in vivo by somatic mutation), for example in the CDRs, particularly CDR3. However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, are grafted onto human framework sequences.
[0078] The antibody molecules described herein can comprise or consist of recombinant human antibodies or antigen-binding fragments thereof. The term "recombinant human antibody", as used herein, is intended to include any human antibody that is prepared, expressed, produced or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant combinatorial human antibody library, antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295), or antibodies prepared, expressed, produced or isolated by any other means involving splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) to modify the V and V regions of the recombinant antibody. H and V L The amino acid sequence of the region is H and V L Recombinant antibodies are sequences derived from and related to sequences, but which may not naturally occur within the human antibody germline repertoire in vivo. Recombinant antibodies can be used in additional embodiments of the compositions and methods of the invention.
[0079] By "isolated antibody" herein is meant an antibody that has been identified and separated and / or recovered from at least one component of its natural environment. For example, an antibody that has been separated or removed from at least one component of the organism, tissue or cell in which it naturally occurs or is naturally produced is an "isolated antibody" for purposes of the present invention. An isolated antibody includes an antibody in situ in a recombinant cell as well as an antibody that has been subjected to at least one purification or isolation step. In certain embodiments, an isolated antibody may be substantially free of other cellular material and / or chemicals. An isolated antibody can be used in additional embodiments of the compositions and methods of the present invention.
[0080] A protein or polypeptide is "substantially pure," "substantially homogeneous," or "substantially purified" if at least about 60-75% of the sample represents a single species of polypeptide. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein will typically comprise about 50%, 60, 70%, 80% or 90% w / w of a protein sample and will usually be greater than about 95%, preferably 99% pure. Protein purity or homogeneity can be demonstrated by several means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample followed by visualization of a single polypeptide band by staining the gel with stains well known in the art. For certain purposes, higher resolution can be achieved by using HPLC or other means well known in the art for purification.
[0081] The term "polypeptide analog or variant" as used herein refers to a polypeptide that is composed of a segment of at least 25 amino acids having substantial identity to a portion of an amino acid sequence and has at least one of the following properties: (1) specific binding to GDF8 under suitable binding conditions, or (2) the ability to block a biological activity of GDF8. Typically, a polypeptide analog or variant contains conservative amino acid substitutions (or insertions or deletions) with respect to the naturally occurring sequence. Analogs are typically at least 20 amino acids long, at least 50, 60, 70, 80, 90, 100, 150 or 200 amino acids long or longer, and often may be as long as a full-length naturally occurring polypeptide.
[0082] Preferred amino acid substitutions are those that (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) change the binding affinity for forming protein complexes, (4) change the binding affinity, and (4) confer or modify other physicochemical or functional properties of such analogs. Analogs can include various mutations of sequences other than the naturally occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) can be made in the naturally occurring sequence (preferably in the portion of the polypeptide outside the domain(s) that form intermolecular contacts). Conservative amino acid substitutions should not substantially change the structural features of the parent sequence (e.g., the amino acid substitutions should not tend to break the helices occurring in the parent sequence or other types of secondary structures that characterize the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Proteins, Structures and Molecular Principles (Creighton 1984 W.H. Freeman and Company, New York; Introduction to Protein Structure (Branden & Tooze, eds., 1991, Garland Publishing, NY); and Thornton et al., 1991 Nature 354:105, each of which is incorporated herein by reference.
[0083] Non-peptide analogs are commonly used in the pharmaceutical industry as drugs with properties similar to those of template peptides. These types of non-peptide compounds are named "peptide mimetics" or "peptidomimetics" (see, for example, Fauchere (1986) J. Adv. Drug Res. 15:29; and Evans et al. (1987) J. Med. Chem. 30:1229, which are incorporated herein by reference). Systematic replacement of one or more amino acids of a consensus sequence with D-amino acids of the same type (e.g., D-lysine instead of L-lysine) can also be used to generate more stable peptides. In addition, constrained peptides that contain consensus sequences or substantially identical consensus sequence variants can be generated by methods known in the art (Rizo et al. (1992) Ann. Rev. Biochem. 61:387, which are incorporated herein by reference), for example, by adding internal cysteine residues that can form intramolecular disulfide bridges that cyclize the peptide.
[0084] As applied to polypeptides, the term "substantial identity" or "substantially identical" means that two peptide sequences share at least about 80% sequence identity, at least about 90%, at least about 95%, at least about 98% or at least about 99% sequence identity when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights. Preferably, non-identical residue positions differ by conservative amino acid substitutions. A "conservative amino acid substitution" is an amino acid substitution in which an amino acid residue is replaced by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. When two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity can be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those skilled in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24:307-331, which is incorporated herein by reference. Examples of groups of amino acids with side chains that have similar chemical properties include: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic-hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; and 6) sulfur-containing side chains: cysteine and methionine. Preferred conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative replacement is any change that has a positive value in the PAM250 log-likelihood matrix, as disclosed in Gonnet et al. (1992) Science 256:1443-45, which is incorporated herein by reference. A "moderately conservative" replacement is any change that has a non-negative value in the PAM250 log-likelihood matrix.
[0085] Sequence similarity, also referred to as sequence identity, for polypeptides is typically measured using sequence analysis software. Protein analysis software uses measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions, to match similar sequences. For example, GCG contains programs such as "Gap" and "Bestfit" that can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species, or between wild-type proteins and their muteins. See, for example, GCG version 6.1. Polypeptide sequences can also be compared using FASTA, a program in GCG version 6.1, using default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignment and percent sequence identity of the best overlap region between query and search sequences (Pearson (2000), see above). Another preferred algorithm is the computer program BLAST, particularly blastp or tblastn, using default parameters when comparing the sequences of the present invention to a database containing a large number of sequences from different organisms. See, for example, Altschul et al. (1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic Acids Res. 25:3389 p. 402, each of which is incorporated herein by reference.
[0086] The length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, at least about 20 residues, at least about 24 residues, at least about 28 residues, or at least about 35 residues. When searching a database containing sequences from a large number of different organisms, it is preferable to compare amino acid sequences.
[0087] In some embodiments, the present invention relates to a method for altering body composition in a subject, comprising administering to the subject a first composition comprising an effective amount of a GDF8 inhibitor, and a second composition comprising an effective amount of an activin A inhibitor.
[0088] In some embodiments, the present invention relates to a method for inducing a loss of fat mass in a subject, comprising administering to the subject a first composition comprising an effective amount of a GDF8 inhibitor, and a second composition comprising an effective amount of an activin A inhibitor.
[0089] In some embodiments, the present invention relates to a method for inducing an increase in muscle mass in a subject, comprising administering to a subject in need thereof a first composition comprising an effective amount of a GDF8 inhibitor, and a second composition comprising an effective amount of an activin A inhibitor.
[0090] In some embodiments, the present invention relates to a method for altering body composition in a subject, comprising administering to the subject a composition comprising an effective amount of a GDF8 inhibitor and an effective amount of an activin A inhibitor.
[0091] In some embodiments, the present invention relates to a method for inducing a loss of fat mass in a subject, comprising administering to the subject a composition comprising an effective amount of a GDF8 inhibitor and an effective amount of an activin A inhibitor.
[0092] In some embodiments, the present invention relates to a method for inducing an increase in muscle mass in a subject, comprising administering to a subject in need thereof a composition comprising an effective amount of a GDF8 inhibitor and an effective amount of an activin A inhibitor.
[0093] In some embodiments, the subject is a human subject. The human subject may be an adult human subject. The subject may be a male or female subject. The subject may be a healthy subject. The subject may be a subject suffering from undesirable fat mass. The subject may be a subject suffering from or at risk of suffering from diseases and disorders characterized by increased fat mass and / or decreased muscle mass or decreased lean body mass. The subject may be a postmenopausal female subject. The subject may be a male or female subject aged 40 years or older, 50 years or older, 60 years or older, or 70 years or older.
[0094] In some embodiments, the present invention relates to methods comprising administering to a subject in need thereof a composition comprising a GDF8 inhibitor and a composition comprising an activin A inhibitor to treat or prevent diseases and disorders characterized by increased fat mass and / or decreased muscle volume or lean body mass.
[0095] In some embodiments of the present invention, the subject has at least one disease or disorder that may be associated with increased fat mass.In some embodiments, the disease or disorder can be selected from the group consisting of obesity, metabolic syndrome, nutritional disorders, high cholesterol, dyslipidemia, cardiovascular disease, cellulitis, cancer (including colon, esophagus, kidney, pancreas, gallbladder, breast or endometrium), polycystic ovarian syndrome, gout, gallbladder disease, sleep apnea, respiratory disorder, asthma, osteoarthritis, cataract, congestive heart failure, enlarged heart, high blood pressure / hypertension, pulmonary embolism, lymphedema, gastroesophageal reflux disease, hernia, chronic renal failure, urinary incontinence, connective tissue disease and fatty liver disease.In another embodiment, the disease or disorder can be sarcopenia.
[0096] GDF8 inhibitors The present invention includes methods for altering body composition, inducing a loss of fat mass, and increasing lean mass in a subject, and methods for treating a disease or disorder characterized by increased fat mass in a subject, comprising administering to the subject a composition comprising an effective amount of a GDF8 inhibitor.
[0097] The term "GDF8" (also referred to as "growth differentiation factor-8" and "myostatin") refers to a protein (mature protein) having the amino acid sequence of SEQ ID NO: 340. In the present invention, a GDF8-specific binding protein specifically binds to GDF8 but does not bind to other ActRIIB ligands such as GDF3, BMP2, BMP4, BMP7, BMP9, BMP10, GDF11, activin A, activin B, activin AB, Nodal, etc.
[0098] As used herein, "GDF8 inhibitor" refers to any agent that binds to or interacts with human GDF8 in vitro or in vivo, and interferes with or inhibits the normal biological function of GDF8.Non-limiting examples of GDF8 inhibitor categories include small molecule GDF8 antagonists, nucleic acid-based inhibitors of GDF8 expression or activity (e.g., siRNA or antisense), peptide-based molecules that specifically interact with GDF8 (e.g., peptibodies), receptor molecules that specifically interact with GDF8, GDF8-binding scaffold molecules, proteins that contain the ligand-binding portion of a receptor that specifically binds to GDF8, and anti-GDF8 aptamers or portions thereof.In a preferred embodiment, the GDF8 inhibitor that can be used in the context of the present invention is an anti-GDF8 antibody or an antigen-binding fragment thereof that specifically binds to human GDF8.Anti-GDF8 antibodies include neutralizing and / or blocking antibodies.The inhibition caused by anti-GDF8 neutralizing and / or blocking antibodies does not need to be complete, as long as it can be detected using a suitable assay.
[0099] As used herein, the expression "anti-GDF8 antibody" also includes multispecific antigen-binding molecules (e.g., bispecific antibodies), in which at least one binding domain (e.g., "binding arm") of the multispecific antigen-binding molecule specifically binds to GDF8.
[0100] Exemplary anti-GDF8 antibodies that can be used in the compositions and methods of the invention include, for example, the fully human anti-GDF8 antibody H4H1657N2, also known as REGN1033 (e.g., an anti-GDF8 antibody comprising heavy and light chain variable regions having the amino acid sequences SEQ ID NO:360 and SEQ ID NO:368, respectively, as set forth in U.S. Pat. No. 8,840,894). Other GDF8 antagonists that can be used in the compositions and methods of the invention include anti-GDF8 antibodies as set forth in US 2006 / 0263354 and U.S. Patent No. 7,807,159 (e.g., an antibody designated 2_112_1, having the ATCC deposit designation PTA-6574, or, e.g., an antibody designated 2_112_K, having the HCVR / LCVR amino acid sequences SEQ ID NOs: 620 and 621); anti-GDF8 antibodies as set forth in U.S. Patent No. 8,999,343 and U.S. Patent Application Publication No. 2013 / 0209489 (e.g., 12A5-5, having the HCVR / LCVR amino acid sequences of SEQ ID NOs: 622 and 623); anti-GDF8 antibodies as set forth in U.S. Patent Application Publication No. 2013 / 0142788 (e.g., an antibody designated 2_112_2, having the ATCC deposit designation PTA-6574, or, e.g., an antibody designated 2_112_K, having the HCVR / LCVR amino acid sequences SEQ ID NOs: 620 and 621); anti-GDF8 antibodies as set forth in U.S. Patent Nos. 8,940,874 and 7,261,893 (e.g., stamulumab / MYO-29 having the HCVR / LCVR amino acid sequences of SEQ ID NOs. 626 and 627); anti-GDF8 antibodies as set forth in U.S. Patent No. 8,415,459 (e.g., RK22 / PF-0625616 having the HCVR / LCVR amino acid sequences of SEQ ID NOs. 628 and 629); anti-GDF8 antibodies as set forth in U.S. Patent No. 7,731,961 (e.g., JA-16 having the CDRs of the HCVR amino acid sequence of SEQ ID NO: 630);anti-GDF8 antibodies (e.g., RK35 having HCVR / LCVR amino acid sequences of SEQ ID NOs: 631 and 632) as described in U.S. Pat. No. 8,496,934 or 7,888,486; anti-GDF8 antibodies (e.g., OGD1.0.0 having HCVR / LCVR amino acid sequences of SEQ ID NOs: 633 and 634) as described in U.S. Pat. No. 8,992,913; anti-GDF8 antibodies (e.g., OGD1.0.0 having HCVR / LCVR amino acid sequences of SEQ ID NOs: 633 and 634) as described in European Patent No. 1773041(B1); Fab molecules, as well as anti-GDF8 antibodies (e.g., C12 having the HCVR / LCVR amino acid sequences of SEQ ID NOs: 635 and 636, C12-N93H and / or 510C2 having the HCVR / LCVR amino acid sequences of SEQ ID NOs: 637 and 638), as set forth in U.S. Patent Nos. 7,635,760 and 8,063,188, and anti-GDF8 antibodies (e.g., 41C1E4 / landgrozumab / LY2495655 having the HCVR / LCVR amino acid sequences of SEQ ID NOs: 639 and 640), as set forth in U.S. Patent No. 7,632,499. In some embodiments, the anti-GDF8 antibody can have the full-length heavy and light chain amino acid sequences of landgrozumab, e.g., SEQ ID NOs: 641 and 642, respectively. In some embodiments, the anti-GDF8 antibody can comprise the three heavy chain CDRs (HCDRs) and three light chain CDRs (LCDRs) of landgrozumab, e.g., according to the Chothia definition, according to SEQ ID NOs: 643 / 644 / 645 / 646 / 647 / 648, respectively;
[0101] In one embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 360 and 376, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0102] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises a light chain variable region (LCVR) amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 322, 368 and 384, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0103] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises an HCVR amino acid sequence and a LCVR amino acid sequence, wherein the HCVR / LCVR sequence pair is selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282, 290 / 298, 306 / 314, 114 / 322, 360 / 368 and 376 / 384.
[0104] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises an HCVR amino acid sequence and an LCVR amino acid sequence, and the HCVR / LCVR sequence pair is: (HCVR / LCVR): 21-E5 (SEQ ID NO: 34 / 42); 21-B9 (SEQ ID NO: 18 / 26); 21-E9 (SEQ ID NO: 98 / 106); 21-A2 (SEQ ID NO: 2 / 10); 22-D3 (SEQ ID NO: 50 / 58); 22-E6 (SEQ ID NO: 66 / 74); 22-G10 (SEQ ID NO: 82 / 90); 1A2 (SEQ ID NO: 226 / 234); 20B12 (SEQ ID NO: 274 / 282); 58C8 (SEQ ID NO: 242 / 244); 250); 19F2 (sequence numbers 258 / 266); 8D12-1 (sequence numbers 114 / 122); 4E3-7 (sequence numbers 194 / 202); 9B11-12 (sequence numbers 162 / 170); 4B9 (sequence numbers 226 / 234); 1H4-5 (sequence numbers 210 / 218); 9B4-3 (sequence numbers 178 / 186); 3E2-1 (sequence numbers 290 / 298); 4G3-25 (sequence numbers 306 / 314); 4B6-6 (sequence numbers 130 / 138); H4H1657N2 (sequence numbers 360 / 368); H4H1669P (sequence numbers 376 / 384).
[0105] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region 3 (HCDR3) domain and a light chain CDR3 (LCDR3) domain, wherein the HCDR3 domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 232, 248, 264, 280, 296, 312, 366, and 382, or at least 90%, at least 95%, at least 98% or or a substantially similar sequence thereof with at least 99% sequence identity, and the LCDR3 domain has an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, 240, 256, 272, 288, 304, 320, 328, 374 and 390, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98% or at least 99% sequence identity. In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises an HCDR3 / LCDR3 amino acid sequence pair selected from the group consisting of SEQ ID NOs: 8 / 16, 24 / 32, 40 / 48, 56 / 64, 72 / 80, 88 / 96, 104 / 112, 120 / 128, 136 / 144, 152 / 160, 168 / 176, 184 / 192, 200 / 208, 216 / 224, 232 / 240, 248 / 256, 264 / 272, 280 / 288, 296 / 304, 312 / 320, 120 / 328, 366 / 374 and 382 / 390.
[0106] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises a heavy chain CDR1 (HCDR1) and CDR2 (HCDR2) domain and a light chain CDR1 (LCDR1) and CDR2 (LCDR2) domain, wherein the HCDR1 domain is selected from the group consisting of SEQ ID NOs: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276, 292, 308, 362, and 378. or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; the HCDR2 domain has an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278, 294, 310, 364 and 380, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; and a substantially similar sequence thereof having at least 98% or at least 99% sequence identity; the LCDR1 domain is an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284, 300, 316, 324, 370, and 386, or at least 90%, at least 95%, at least 98%, or at least 99% sequence identity. and the LCDR2 domain has an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286, 302, 318, 326, 372 and 388, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.In another embodiment, the HCDR1, HCDR2 and HCDR3 domains have respective amino acid sequence combinations selected from the group consisting of SEQ ID NOs: 36 / 38 / 40, 116 / 118 / 120, 228 / 230 / 232, 362 / 364 / 366 and 378 / 380 / 382; and the LCDR1, LCDR2 and LCDR3 domains have respective amino acid sequence combinations selected from the group consisting of SEQ ID NOs: 44 / 46 / 48, 124 / 126 / 128, 236 / 238 / 240, 370 / 372 / 374 and 386 / 388 / 390.
[0107] In yet another embodiment, the heavy and light chain CDR domains (HCDR1 / HCDR2 / HCDR3 / LCDR1 / LCDR2 / LCDR3) of the anti-GDF8 antibody or antigen-binding fragment thereof have an amino acid sequence combination selected from the group consisting of SEQ ID NOs: 36 / 38 / 40 / 44 / 46 / 48 (e.g., 21-E5), 116 / 118 / 120 / 124 / 126 / 128 (e.g., 8D12), 228 / 230 / 232 / 236 / 238 / 240 (e.g., 1A2), 362 / 364 / 366 / 370 / 372 / 374 (e.g., H4H1657N2) and 378 / 380 / 382 / 386 / 388 / 390 (e.g., H4H1669P).
[0108] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises heavy and light chain CDR domains contained within a heavy and light chain variable region (HCVR / LCVR) amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282, 290 / 298, 306 / 314, 114 / 322, 360 / 368 and 376 / 384.
[0109] Methods and techniques for identifying CDRs in HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs in the specified HCVR and / or LCVR amino acid sequences disclosed herein. Exemplary conventions that can be used to identify the boundaries of CDRs include, for example, Kabat definition, Chothia definition and AbM definition. In general terms, Kabat definition is based on sequence variability, Chothia definition is based on the location of structural loop regions, and AbM definition is a compromise between Kabat and Chothia approaches. See, for example, Kabat, "Sequences of Proteins of Immunological Interest", National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J. Mol. Biol. 273: 927-948 (1997); and Martin et al., Proc. Natl. Acad. Sci. USA 86: 9268-9272 (1989). Public databases are also available to identify CDR sequences within antibodies.
[0110] In one embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises a HCVR having an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 17, 33, 49, 65, 81, 97, 113, 129, 145, 161, 177, 193, 209, 225, 241, 257, 273, 289, 305, 359 and 375, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0111] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises an LCVR having an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 9, 25, 41, 57, 73, 89, 105, 121, 137, 153, 169, 185, 201, 217, 233, 249, 265, 281, 297, 313, 321, 367 and 383, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0112] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises a HCVR / LCVR pair having an amino acid sequence encoded by a nucleic acid molecule pair selected from the group consisting of SEQ ID NOs: 1 / 9, 17 / 25, 33 / 41, 49 / 57, 65 / 73, 81 / 89, 97 / 105, 113 / 121, 129 / 137, 145 / 153, 161 / 169, 177 / 185, 193 / 201, 209 / 217, 225 / 233, 241 / 249, 257 / 265, 273 / 281, 289 / 297, 305 / 313, 113 / 321, 359 / 367 and 375 / 383.
[0113] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof has an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7, 23, 39, 55, 71, 87, 103, 119, 135, 151, 167, 183, 199, 215, 231, 247, 263, 279, 295, 311, 365, and 381, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity. The present invention includes a CDR3 domain and an LCDR3 domain having an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 15, 31, 47, 63, 79, 95, 111, 127, 143, 159, 175, 191, 207, 223, 239, 255, 271, 287, 303, 319, 327, 373 and 389, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity. In one embodiment, the HCDR3 / LCDR3 domain pair has an amino acid sequence encoded by a nucleic acid sequence pair selected from the group consisting of SEQ ID NOs: 7 / 15, 23 / 31, 39 / 47, 55 / 63, 71 / 79, 87 / 95, 103 / 111, 119 / 127, 135 / 143, 151 / 159, 167 / 175, 183 / 191, 199 / 207, 215 / 223, 231 / 239, 247 / 255, 263 / 271, 279 / 287, 295 / 303, 311 / 319, 119 / 327, 365 / 373 and 381 / 389.
[0114] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises HCDR1 and HCDR2 domains and LCDR1 and LCDR2 domains, wherein the HCDR1 domain is a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 3, 19, 35, 51, 67, 83, 99, 115, 131, 147, 163, 179, 195, 211, 227, 243, 259, 275, 291, 307, 361, and 377, or at least 90% and the HCDR2 domain is a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 5, 21, 37, 53, 69, 85, 101, 117, 133, 149, 165, 181, 197, 213, 229, 245, 261, 277, 293, 309, 363, and 379, or a substantially similar sequence having at least 90%, at least 95% sequence identity to any of the sequences. , or a substantially similar sequence thereof having at least 98% or at least 99% sequence identity, and the LCDR1 domain is a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 11, 27, 43, 59, 75, 91, 107, 123, 139, 155, 171, 187, 203, 219, 235, 251, 267, 283, 299, 315, 323, 369 and 385, or at least 90%, at least 95% , and a substantially similar sequence thereof having at least 98% or at least 99% sequence identity, and the LCDR2 domain has an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 13, 29, 45, 61, 77, 93, 109, 125, 141, 157, 173, 189, 205, 221, 237, 253, 269, 285, 301, 317, 325, 371 and 387.
[0115] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof comprises heavy and light chain CDR domains (HCDR1 / HCDR2 / HCDR3 / LCDR1 / LCDR2 / LCDR3) having an amino acid sequence combination encoded by the nucleic acid sequence set of SEQ ID NOs: 35 / 37 / 39 / 43 / 45 / 47, 115 / 117 / 119 / 123 / 125 / 127, 227 / 229 / 231 / 235 / 237 / 239, 361 / 363 / 365 / 369 / 371 / 373 or 377 / 379 / 381 / 385 / 387 / 389.
[0116] In a preferred embodiment, an anti-GDF8 antibody or antigen-binding fragment thereof that specifically binds to GDF8 comprises an HCDR of the heavy chain variable region (HCVR) that comprises SEQ ID NO: 360, and an LCDR of the light chain variable region (LCVR) that comprises SEQ ID NO: 368. In another embodiment, an anti-GDF8 antibody or antigen-binding fragment thereof that specifically binds to GDF8 comprises three HCDRs that comprise SEQ ID NO: 362, SEQ ID NO: 364, and SEQ ID NO: 366, and three LCDRs that comprise SEQ ID NO: 370, SEQ ID NO: 372, and SEQ ID NO: 374.
[0117] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof is a fully human or humanized antibody or antibody fragment that binds to GDF8 with an affinity (expressed as a dissociation constant "KD") of about 1 nM or less as measured by a surface plasmon resonance assay (e.g., BIACORE™). In certain embodiments, the antibodies of the invention exhibit a KD of about 700 pM or less; about 500 pM or less; about 320 pM or less; about 160 pM or less; about 100 pM or less; about 50 pM or less; about 10 pM or less; or about 5 pM or less.
[0118] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof is a fully human or humanized monoclonal antibody (mAb) that specifically binds to and inhibits human GDF8 and exhibits an IC50 of about 10 nM or less; about 5 nM or less; about 3 nM or less; about 2 nM or less; about 1 nM or less; about 500 pM or less; or about 200 pM or less as measured by a GDF8-induced luciferase assay.
[0119] In one embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof has an altered glycosylation pattern. In some applications, modification to remove undesired glycosylation sites may be useful, or the antibody lacks fucose moieties present in the oligosaccharide chain, for example, to increase antibody-dependent cellular cytotoxicity (ADCC) function (Shield et al. (2002) JBC 277:26733). In other applications, galactosylation modification can be made to modify complement-dependent cytotoxicity (CDC).
[0120] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof competes for specific binding to GDF8 with another antibody that comprises an HCDR1 / HCDR2 / HCDR3 / LCDR1 / LCDR2 / LCDR3 domain combination having an amino acid sequence selected from the group consisting of SEQ ID NOs: 36 / 38 / 40 / 44 / 46 / 48, 116 / 118 / 120 / 124 / 126 / 128, 228 / 230 / 232 / 236 / 238 / 240, 362 / 364 / 366 / 370 / 372 / 374 or 378 / 380 / 382 / 386 / 388 / 390. In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof competes for specific binding to GDF8 with another antibody comprising the HCVR / LCVR amino acid sequence pair of SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282, 290 / 298, 306 / 314, 114 / 322, 360 / 368 or 376 / 384.
[0121] In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof recognizes an epitope in GDF8 recognized by another antibody comprising an HCDR1 / HCDR2 / HCDR3 / LCDR1 / LCDR2 / LCDR3 domain combination having an amino acid sequence selected from the group consisting of SEQ ID NOs: 36 / 38 / 40 / 44 / 46 / 48, 116 / 118 / 120 / 124 / 126 / 128, 228 / 230 / 232 / 236 / 238 / 240, 362 / 364 / 366 / 370 / 372 / 374 or 378 / 380 / 382 / 386 / 388 / 390. In another embodiment, the anti-GDF8 antibody or antigen-binding fragment thereof recognizes an epitope in GDF8 recognized by another antibody comprising the HCVR / LCVR amino acid sequence pair of SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282, 290 / 298, 306 / 314, 114 / 322, 360 / 368 or 376 / 384.
[0122] Activin A Inhibitors The present invention includes methods for altering body composition, inducing a loss of fat mass, and / or increasing lean mass in a subject, as well as methods for treating a disease or disorder characterized by increased fat mass in a subject, comprising administering to the subject a composition comprising an effective amount of an activin A inhibitor.
[0123] As used herein, "activin A inhibitor" refers to any agent that binds to or interacts with human activin A in vitro or in vivo, and interferes with or inhibits the normal biological function of activin A. Non-limiting examples of categories of activin A inhibitors include small molecule activin A antagonists, nucleic acid-based inhibitors of activin A expression or activity (e.g., siRNA or antisense), peptide-based molecules that specifically interact with activin A (e.g., peptibodies), receptor molecules that specifically interact with activin A, activin A binding scaffold molecules, proteins that contain the ligand-binding portion of a receptor that specifically binds to activin A, and anti-activin A aptamers or portions thereof. In a preferred embodiment, the activin A inhibitor that can be used in the context of the present invention is an anti-activin A antibody or an antigen-binding fragment thereof that specifically binds to human activin A. Anti-activin A antibodies include neutralizing and / or blocking antibodies. The inhibition caused by anti-activin A neutralizing and / or blocking antibodies need not be complete, so long as it is detectable using an appropriate assay.
[0124] Activin is a homo- and heterodimeric molecule that contains βA and / or βB subunits. The βA subunit has the amino acid sequence of SEQ ID NO: 617, and the βB subunit has the amino acid sequence of SEQ ID NO: 619. Activin A is a homodimer of two βA subunits; activin B is a homodimer of two βB subunits; activin AB is a heterodimer of one βA subunit and one βB subunit. An anti-activin A antibody or antigen-binding fragment thereof specifically binds to the βA subunit. Since the βA subunit is found in both activin A and activin AB molecules, an "anti-activin A antibody or antigen-binding fragment thereof" can specifically bind to activin AB (due to its interaction with the βA subunit) along with activin A. Thus, an anti-activin A antibody or antigen-binding fragment thereof specifically binds to activin A, or activin A and activin AB, but does not bind to other ActRIIB ligands, such as activin B, GDF3, GDF8, BMP2, BMP4, BMP7, BMP9, BMP10, GDF11, or Nodal.
[0125] In some embodiments, as described in US Patent No. 9,718,881, anti-activin A antibody or its antigen-binding fragment is used.The exemplary anti-activin A antibody that can be used in the compositions and methods of the present invention includes, for example, fully human anti-activin antibody H4H10446P2, also known as REGN2477 (for example, as described in US Patent No. 9,718,881, the anti-activin A antibody comprises heavy and light chain variable regions having amino acid sequences SEQ ID NO: 162 and SEQ ID NO: 146, respectively).
[0126] Table 2 lists the heavy and light chain variable region amino acid sequence pairs of selected anti-activin A antibodies that can be used in the compositions and methods of the invention, and their corresponding antibody identifiers. The corresponding nucleic acid sequence identifiers are listed in Table 3.
[0127] [Table 1]
[0128] [Table 2]
[0129] In one embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 393, 409, 425, 441, 457, 473, 489, 497, 505, 513, 521, 529, 545, 553, 561, 569, 577, 585 and 593, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0130] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 401, 417, 433, 449, 465, 481, 537 and 601, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0131] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises a HCVR and LCVR (HCVR / LCVR) amino acid sequence pair selected from the group consisting of SEQ ID NOs: 393 / 401, 409 / 417, 425 / 433, 441 / 449, 457 / 465, 473 / 481, 489 / 481, 497 / 481, 505 / 481, 513 / 481, 521 / 481, 529 / 537, 545 / 537, 553 / 537, 561 / 537, 569 / 537, 577 / 537, 585 / 537 and 593 / 601.
[0132] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises a heavy chain CDR3 (HCDR3) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 399, 415, 431, 447, 463, 479, 495, 503, 511, 519, 527, 535, 551, 559, 567, 575, 583, 591 and 599, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98% or at least 99% sequence identity; and a light chain CDR3 (LCDR3) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 407, 423, 439, 455, 471, 487, 543 and 607, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0133] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises an HCDR3 / LCDR3 amino acid sequence pair selected from the group consisting of SEQ ID NOs: 399 / 407, 415 / 423, 431 / 439, 447 / 455, 463 / 471, 479 / 487, 495 / 487, 503 / 487, 511 / 487, 519 / 487, 527 / 487, 535 / 543, 551 / 543, 559 / 543, 567 / 543, 575 / 543, 583 / 543, 591 / 543 and 599 / 607.
[0134] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises a heavy chain CDR1 (HCDR1) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 395, 411, 427, 443, 459, 475, 491, 499, 507, 515, 523, 531, 547, 555, 563, 571, 579, 587 and 595, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; an amino acid sequence selected from the group consisting of SEQ ID NOs: 397, 413, 429, 445, 461, 477, 493, 501, 509, 517, 525, 533, 549, 557, 565, 573, 581, 589 and 597, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity. a heavy chain CDR2 (HCDR2) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 403, 419, 435, 451, 467, 483, 539 and 603, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; and a light chain CDR2 (LCDR2) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 405, 421, 437, 453, 469, 485, 541 and 605, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0135] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof is selected from the group consisting of SEQ ID NOs: 395-397-8-403-405-407; 411-413-415-419-421-423; 36-429-431-435-437-439; 443-445-447-451-453-455; 459-461-463-467 -469-471;475-477-479-483-485-487;491-493-495-483-485-487;499-501-503-483-485-487;507-509-511-483-485-487;515-517-519-483-485-487;523-525-527-48 3-485-487;531-533-535-539-541-543;547-549-551-539-541-543;555-557-559-5 39-541-543(H4H10446P2);563-565-567-539-541-543;571-573-575-539-541-543;5 79-581-583-539-541-543; 587-589-591-539-541-543; and 595-597-599-603-605-607.
[0136] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises heavy and light chain CDR domains contained within a heavy and light chain variable region (HCVR / LCVR) sequence pair selected from the group consisting of SEQ ID NOs: 393 / 401, 409 / 417, 425 / 433, 441 / 449, 457 / 465, 473 / 481, 489 / 481, 497 / 481, 505 / 481, 513 / 481, 521 / 481, 529 / 537, 545 / 537, 553 / 537, 561 / 537, 569 / 537, 577 / 537, 585 / 537 and 593 / 601.
[0137] In one embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises a HCVR having an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 392, 408, 424, 440, 456, 472, 488, 496, 504, 512, 520, 528, 544, 552, 560, 568, 576, 584 and 592, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0138] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises an LCVR having an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 400, 416, 432, 448, 464, 480, 536 and 600, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0139] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises an HCVR and a LCVR, wherein the HCVR / LCVR pair has an amino acid sequence encoded by a nucleic acid sequence pair selected from the group consisting of SEQ ID NOs: 392 / 400, 408 / 416, 424 / 432, 440 / 448, 456 / 464, 472 / 480, 488 / 480, 496 / 480, 504 / 480, 512 / 480, 520 / 480, 528 / 536, 544 / 536, 552 / 536, 560 / 536, 568 / 536, 576 / 536, 584 / 536 and 592 / 600.
[0140] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises an HCDR3 domain having an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 398, 414, 430, 446, 462, 478, 498, 502, 510, 518, 526, 534, 550, 558, 566, 574, 582, 590 and 598, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98% or at least 99% sequence identity, and an LCDR3 domain having an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 406, 422, 435, 454, 470, 486, 542 and 606, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98% or at least 99% sequence identity. In one embodiment, the HCDR3 / LCDR3 domain set has an amino acid sequence encoded by a nucleic acid sequence pair selected from the group consisting of SEQ ID NOs: 398 / 406, 414 / 422, 430 / 438, 446 / 454, 462 / 470, 478 / 486, 494 / 486, 502 / 486, 510 / 486, 518 / 486, 526 / 486, 534 / 542, 550 / 542, 558 / 542, 566 / 542, 574 / 542, 582 / 542, 590 / 542 and 598 / 606.
[0141] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises HCDR1 and HCDR2 domains and LCDR1 and LCDR2 domains, wherein the HCDR1 domain is a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 394, 410, 426, 442, 458, 474, 490, 498, 506, 514, 522, 530, 546, 554, 562, 570, 578, 586, and 594, or at least and wherein the HCDR2 domain is a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 396, 412, 428, 444, 460, 476, 492, 500, 508, 516, 524, 532, 548, 556, 564, 572, 580, 588 and 596, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto. or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; the LCDR1 domain has an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 402, 418, 434, 450, 466, 482, 538 and 602, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; and the LCDR2 domain has an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 404, 420, 436, 452, 468, 484, 540 and 604, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0142] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof is selected from the group consisting of SEQ ID NOs: 394 / 396 / 398 / 402 / 404 / 406, 410 / 412 / 414 / 418 / 420 / 422, 426 / 428 / 430 / 434 / 436 / 438, 442 / 444 / 446 / 450 / 452 / 454, 458 / 460 / 462 / 466 / 468 / 470, 474 / 476 / 478 / 482 / 484 / 486, 490 / 492 / 494 / 482 / 484 / 486, 498 / 500 / 502 / 482 / 484 / 486, 506 / 508 / 510 / 482 / 484 / 486, 514 / 516 / 518 / 482 / 484 / 486, 522 / 524 / 526 / 482 / 4 84 / 486, 530 / 532 / 534 / 538 / 540 / 542, 546 / 548 / 550 / 538 / 540 / 542, 554 / 556 / 558 / 538 / 540 / 542, 562 / 564 / 566 / 538 / 540 / 542, 570 / 572 / 574 / 538 / 540 / 542, 578 / 580 / 582 / 538 / 540 / 542, 586 / 588 / 590 / 538 / 540 / 542 and 594 / 596 / 598 / 602 / 604 / 606.
[0143] In one embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises the HCVR and LCVR (HCVR / LCVR) amino acid sequence pair of SEQ ID NO: 553 / 537, and the anti-GDF8 antibody or antigen-binding fragment thereof comprises the HCVR and LCVR (HCVR / LCVR) amino acid sequence pair of SEQ ID NO: 360 / 368.
[0144] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, each having the amino acid sequence of SEQ ID NO: 555-557-559-539-541-543 (H4H10446P2), and the anti-GDF8 antibody or antigen-binding fragment thereof comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, each having the amino acid sequence of SEQ ID NO: 362 / 364 / 366 / 370 / 372 / 374 (e.g., H4H1657N2).
[0145] In another embodiment, the anti-activin A antibody or antigen-binding fragment thereof has an altered glycosylation pattern. In some applications, modification to remove undesired glycosylation sites may be useful, or the antibody lacks fucose moieties present in the oligosaccharide chain, for example, to increase antibody-dependent cellular cytotoxicity (ADCC) function (Shield et al. (2002) JBC 277:26733). In other applications, galactosylation modification can be made to modify complement-dependent cytotoxicity (CDC).
[0146] The fully human anti-activin A and / or anti-GDF8 antibodies described herein may contain one or more amino acid substitutions, insertions and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences. Such mutations can be easily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available, for example, from public antibody sequence databases. The compositions and methods of the present invention, in additional embodiments, use antibodies and antigen-binding fragments thereof derived from any of the amino acid sequences disclosed herein, in which one or more amino acids in one or more framework and / or CDR regions are backmutated to the corresponding germline residue(s) or to a conservative amino acid substitution (natural or non-natural) of the corresponding germline residue(s) (such sequence changes are referred to herein as "germline backmutations"). Starting from the heavy and light chain variable region sequences described herein, one skilled in the art can easily produce a large number of antibodies and antigen-binding fragments containing one or more individual germline backmutations or combinations thereof. In certain embodiments, all of the framework and / or CDR residues in the VH and / or VL domain are mutated back to germline sequence.In other embodiments, only certain residues are mutated back to germline sequence, for example, only the mutated residues found in the first 8 amino acids of FR1 or the last 8 amino acids of FR4, or only the mutated residues found in CDR1, CDR2 or CDR3.Furthermore, the antibody and antigen-binding fragments used in the compositions and methods of the present invention can contain any combination of two or more germline back mutations in the framework and / or CDR regions, i.e., certain individual residues are mutated back to germline sequence, while certain other residues that differ from germline sequence are maintained.Once obtained, antibodies and antigen-binding fragments containing one or more germline back mutations can be readily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc. Antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present invention.
[0147] The compositions and methods of the invention, in additional embodiments, employ anti-GDF8 and / or anti-activin A antibodies (or antigen-binding fragments thereof) that comprise variants of any of the HCVR, LCVR and / or CDR amino acid sequences described herein with one or more conservative substitutions. For example, the anti-GDF8 and / or anti-activin A antibodies used in the compositions and methods of the invention, in some embodiments, have HCVR, LCVR and / or CDR amino acid sequences that have, e.g., 10 or less, 8 or less, 6 or less, 4 or less, etc., conservative amino acid substitutions compared to any of the HCVR, LCVR and / or CDR amino acid sequences described herein.
[0148] bispecific antibody Bispecific antibodies (bsAbs) combine the specificity of two antibodies and bind to different antigens or epitopes together. Two or more antigen recognition elements are engineered into a single antibody. In one embodiment of the method of the present invention, the composition comprises an antibody comprising a GDF8-specific binding domain and an activin A-specific binding domain. The term (antigen) "specific binding domain" as used herein includes (i) an antigen-binding fragment of an antibody molecule, (ii) a peptide (e.g., a peptibody) that specifically interacts with a particular antigen, and / or (iii) a polypeptide that comprises or consists of a ligand-binding portion of a receptor that specifically binds to a particular antigen. For example, bispecific antibodies are included that have one arm that comprises a first heavy chain variable region / light chain variable region (HCVR / LCVR) pair that specifically binds to GDF8 and another arm that comprises a second HCVR / LCVR pair that specifically binds to activin A.
[0149] Bispecific antibodies can be prepared according to known methods, including chemical cross-linking, hybrid hybridomas / quadromas, knobs into holes, CrossMab, dual variable domain immunoglobulins, recombinant engineering (tandem single chain variable fragments / diabodies), and dock and lock. Other exemplary bispecific formats that can be used in the context of the present invention include, without limitation, IgG-scFv fusions, dual variable domain (DVD)-Ig, common light chain, CrossFab, (SEED)body, leucine zipper, Duobody, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab2 bispecific formats (see, for example, Klein et al., mAbs 4:6, pp. 1-11 (2012) and references cited therein, for a review of the aforementioned formats). Bispecific antibodies can also be constructed using peptide / nucleic acid conjugation, for example, using unnatural amino acids with orthogonal chemical reactivity to generate site-specific antibody-oligonucleotide conjugates that then self-assemble into multimeric complexes with defined composition, valency and geometry (see, e.g., Kazane et al., J Am Chem Soc. 135(1):340-346 (2013)).
[0150] specific binding "Specifically binds" and like terms are used herein to mean that an antigen-specific binding protein or antigen-specific binding domain has a dissociation constant (K D) and does not bind to other unrelated antigens under normal test conditions. An "unrelated antigen" is a protein, peptide, or polypeptide that has less than 95% amino acid identity with each other. Methods for determining whether two molecules specifically bind to each other are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, as used in the context of the present invention, an antigen-specific binding protein or antigen-specific binding domain has a K of less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, less than about 50 pM, less than about 40 pM, less than about 30 pM, less than about 20 pM, less than about 10 pM, less than about 5 pM, less than about 4 pM, less than about 2 pM, less than about 1 pM, less than about 0.5 pM, less than about 0.2 pM, less than about 0.1 pM or less than about 0.05 pM as measured in a surface plasmon resonance assay. D and includes antibodies or antigen-binding fragments thereof that bind to a specific antigen (e.g., GDF8, activin A) or a portion thereof.
[0151] Antibody binding (of antigen) is a measure of affinity, K D It can be quantified in units of K D The lower the value, the higher the binding affinity of the antibody. D The term "as used herein is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction. Surface plasmon resonance can be used to measure ligand binding, e.g., antibody-antigen interactions.
[0152] The term "surface plasmon resonance" as used herein refers to an optical phenomenon that allows analysis of real-time biospecific interactions by detection of alterations in protein concentration within a biosensor matrix, for example, using the BIACORE™ system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ).
[0153] The term "epitope" includes any determinant, preferably a polypeptide determinant, capable of specific binding to an immunoglobulin or T-cell receptor. In certain embodiments, epitopic determinants include chemically active surface groupings of molecules, such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and in certain embodiments, can have specific three-dimensional structural features and / or specific charge characteristics. An epitope is the region of an antigen that is bound by an antibody. In certain embodiments, an antibody is said to specifically bind an antigen when it preferentially recognizes its target antigen in a complex mixture of proteins and / or macromolecules. For example, K D But, 10 -8 M or less, 10 -9 M or less or 10 -10 An antibody is said to specifically bind to an antigen when M is less than or equal to M.
[0154] Preparation of human antibodies Methods for generating monoclonal antibodies, including fully human monoclonal antibodies, are known in the art. Any such known method can be used in the context of the present invention to generate human antibodies that specifically bind to GDF8 and / or activin A.
[0155] Using VELOCIMMUNE™ technology or any other known method for generating monoclonal antibodies, high affinity chimeric antibodies against GDF8 and / or activin A are first isolated, having human variable regions and mouse constant regions. As described in the experimental section below, the antibodies are characterized and selected for desired characteristics including affinity, selectivity, epitope, etc. The mouse constant regions are replaced with the desired human constant regions to generate fully human antibodies of the invention, e.g., wild-type or modified IgG1 or IgG4. The constant regions selected can vary depending on the specific application, but the high affinity antigen binding and target specificity characteristics reside in the variable regions.
[0156] In general, the antibodies used in the methods of the invention possess very high affinity, typically on the order of 10 as measured by binding to antigen immobilized on a solid phase or in solution phase. -12 ~about 10 -9 K of M D Holds.
[0157] Pharmaceutical Compositions and Methods of Administration The present invention includes a method for modifying the body composition of a subject. As used herein, the phrase "modifying body composition" refers to a change in one or more of lean mass, fat mass, and / or bone mass in a subject. In some embodiments, the body composition in a subject can be modified by administering an effective amount of a GDF8 inhibitor and an activin A inhibitor to the subject. The lean mass can be, for example, thigh muscle volume, appendicular lean mass, or total lean mass, etc. In some aspects, the thigh muscle volume can refer to the thigh muscle tissue volume excluding intramuscular adipose tissue and large blood vessels. In some aspects, the thigh muscle volume can refer to the thigh muscle tissue volume including intramuscular adipose tissue and large blood vessels. In some aspects, the appendicular lean mass can be calculated, for example, by the aLBM equation. In some aspects, the appendicular lean mass can be calculated by the sum of the lean mass of the arms and legs. The fat mass can be, for example, total fat mass, android fat mass, the sum of intramuscular and perimuscular adipose tissue (IMAT), subcutaneous adipose tissue volume, the sum of the fat mass of the arms and legs, thigh intramuscular adipose tissue, etc. Bone mass may be, for example, total bone mineral density (BMD) mass, total bone mineral content (BMC) mass, etc. In some embodiments, the alteration of body composition includes an increase in muscle mass and / or a decrease in fat mass. In some embodiments, the alteration of body composition includes both an increase in muscle mass and a decrease in fat mass. In some embodiments, the alteration of body composition includes both an increase in muscle mass and a decrease in fat mass without a decrease in bone mass. In some embodiments, the alteration of body composition includes an increase in bone mineral content. In some embodiments, the alteration of body composition includes a decrease in total fat mass, android fat mass, and / or subcutaneous fat mass. In some embodiments, the alteration of body composition includes a decrease in total fat mass, android fat mass, and / or subcutaneous fat mass without a decrease in thigh intramuscular adipose tissue volume.
[0158] The present invention includes a method for modifying body composition in a subject, for example, for inducing a decrease in fat mass, and a method for treating a disease or disorder characterized by increased fat mass, comprising administering to the subject a first composition comprising an effective amount of a GDF8 inhibitor and a second composition comprising an effective amount of an activin A inhibitor. The first and second compositions can be administered to the subject simultaneously or sequentially. The first and second compositions can also be combined into a third composition before administration. Thus, in certain embodiments, a composition comprising both a GDF8 inhibitor and an activin A inhibitor can be administered to the subject. The GDF8 inhibitor in such a composition can be, for example, an anti-GDF8 antibody. The activin A inhibitor in such a composition can be, for example, an anti-activin A antibody.
[0159] The pharmaceutical compositions of the present invention are formulated with suitable carriers, excipients, and other agents that provide suitable entry, delivery, tolerance, etc. Numerous suitable formulations can be found in formularies known to every pharmacist: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. Such formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic)-containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the above mixtures may be suitable in the treatment and therapy according to the present invention, provided that the active ingredients in the formulation are not inactivated by the formulation and the formulation is physiologically compatible and acceptable to the route of administration. See also Powell et al., "Compendium of excipients for parenteral formulations," PDA (1998) J Pharm Sci Technol 52:238-311.
[0160] A variety of delivery systems are known and can be used to administer the pharmaceutical compositions of the present invention, including, for example, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis (see, for example, Wu et al., 1987, J. Biol. Chem. 262:4429-4432). Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions can be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other biologically active agents.
[0161] The pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously using a standard needle and syringe. In addition, for subcutaneous delivery, a pen delivery device can easily be used to deliver the pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge containing the pharmaceutical composition. Once the pharmaceutical composition in the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device is pre-filled with the pharmaceutical composition held in a reservoir within the device. Once the pharmaceutical composition is used and the reservoir is empty, the entire device is discarded.
[0162] Numerous reusable pen and autoinjector type delivery devices have application in the subcutaneous delivery of the pharmaceutical compositions of the present invention. Examples include AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK), DISETRONIC™ pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75 / 25™ pen, HUMALOG™ pen, HUMALIN 70 / 30™ pen (Eli Lilly and Co., Indianapolis, IN), NOVOPEN™ I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), BD™ pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPEN™, OPTIPEN PRO™, OPTIPEN™, to name just a few. Examples of disposable pen-type delivery devices that have application in subcutaneous delivery of the pharmaceutical composition of the present invention include, but are not limited to, SOLOSTAR pen (Sanofi-Aventis), FLEXPEN (Novo Nordisk), and KWIKPEN (Eli Lilly), SURECLICK autoinjector (Amgen, Thousand Oaks, CA), PENLET (Haselmeier, Stuttgart, Germany), EPIPEN (Dey, LP), and HUMIRA pen (Abbott Labs, Abbott Park IL), to name just a few.
[0163] In certain circumstances, the pharmaceutical compositions of the present invention can be delivered in a controlled release system. In one embodiment, a pump can be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201). In another embodiment, a polymeric material can be used; see Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Florida. In yet another embodiment, the controlled release system can be placed close to the target of the composition, thus requiring only a fraction of the systemic dose (see, for example, Goodson, 1984, in Medical Applications of Controlled Release, supra, Vol. 2, pp. 115-138). Other controlled release systems are described in the review by Langer, 1990, Science 249:1527-1533.
[0164] The injectable preparations may include dosage forms for intravenous, subcutaneous, intradermal and intramuscular injections, drip infusions, and the like. Such injectable preparations may be prepared by known methods. For example, the injectable preparations may be prepared by dissolving, suspending or emulsifying, for example, the above-described antibody or its salt in a sterile aqueous medium or oily medium conventionally used for injections. As aqueous media for injection, there are physiological saline, isotonic solutions, and the like containing glucose and other auxiliary agents, which may be used in combination with suitable solubilizing agents such as alcohol (e.g., ethanol), polyhydric alcohol (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)]. As oily media, for example, sesame oil, soybean oil, and the like may be used in combination with solubilizing agents such as benzyl benzoate, benzyl alcohol, and the like. The injectable preparations thus prepared are preferably filled into suitable ampoules.
[0165] Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms with unit doses suitable for the dosage of the active ingredient.Such dosage forms with unit doses include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.
[0166] Dosage The amount of active ingredient (e.g., anti-GDF8 antibody and / or anti-activin A antibody) that can be administered to a subject is generally a therapeutically effective amount. The term "effective amount" is the concentration or amount of active ingredient, e.g., antibody or antigen-binding fragment of antibody, that results in the achievement of a specific described purpose. The term "effective amount" is used interchangeably with the term "therapeutically effective amount" and refers to the concentration or amount of active ingredient, e.g., antibody or antigen-binding fragment thereof, that is effective in achieving the described therapeutic effect. The (therapeutically) effective amount can be determined empirically.
[0167] As used herein, the phrase "therapeutically effective amount" or "effective amount" refers to a dose of an antigen-specific binding protein and / or antigen-binding molecule (e.g., an antibody) that results in a detectable reduction in fat mass. An effective amount, in certain embodiments, can also result in an increase in one or more of the following parameters: body weight, muscle mass (e.g., tibialis anterior [TA] muscle mass, gastrocnemius [GA] muscle mass, quadriceps gastrocnemius [Quad] muscle mass, appendicular lean body mass, etc.), muscle volume (e.g., thigh muscle volume), muscle strength / power and / or muscle function, and glucose tolerance.
[0168] A "therapeutically effective amount" or "effective amount" of a GDF8 inhibitor (e.g., an anti-GDF8 antibody) and / or an activin A inhibitor (e.g., an anti-activin A antibody) includes, for example, an amount of a GDF8 inhibitor and / or an activin A inhibitor that, when administered to a subject, causes a reduction in total fat mass of at least about 2% to 8%, at least 2.5% to 6%, at least 3% to 4%, or at least about 2.0%, at least about 2.5%, at least about 3.0%, or at least about 3.5% or more. For example, a "therapeutically effective amount" or "effective amount" of a GDF8 inhibitor (e.g., an anti-GDF8 antibody) and / or an activin A inhibitor (e.g., an anti-activin A antibody) includes, for example, an amount of a GDF8 inhibitor and / or an activin A inhibitor that, when administered to a subject, causes a reduction in total fat mass of at least about 3.5% or more.
[0169] In some embodiments, a "therapeutically effective amount" or "effective amount" of a GDF8 inhibitor (e.g., an anti-GDF8 antibody) and / or an activin A inhibitor (e.g., an anti-activin A antibody) includes, for example, an amount of a GDF8 inhibitor and / or an activin A inhibitor that, when administered to a subject, causes a reduction in android fat mass of at least about 2% to 8%, at least 2.5% to 6%, at least 3% to 4%, or at least about 2.0%, at least about 2.5%, at least about 3.0%, or at least about 3.5% or more. For example, a "therapeutically effective amount" or "effective amount" of a GDF8 inhibitor (e.g., an anti-GDF8 antibody) and / or an activin A inhibitor (e.g., an anti-activin A antibody) includes, for example, an amount of a GDF8 inhibitor and / or an activin A inhibitor that, when administered to a subject, causes a reduction in android fat mass of at least about 3.5%.
[0170] In certain embodiments, this amount also results in an increase in TA or GA muscle mass of at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60% or more compared to a control-treated subject.
[0171] In some embodiments, a "therapeutically effective amount" or "effective amount" of a GDF8 inhibitor (e.g., an anti-GDF8 antibody) and / or an activin A inhibitor (e.g., an anti-activin A antibody) includes, for example, an amount of GDF8 inhibitor and / or activin A inhibitor that, when administered to a subject, causes an increase in thigh muscle volume of at least about 2%-8%, 2.5%-6%, 3%-4%, or at least 2.0%, at least 2.5%, at least 3.0% or at least 3.5% or more.
[0172] In some embodiments, a "therapeutically effective amount" or "effective amount" of a GDF8 inhibitor (e.g., an anti-GDF8 antibody) and / or an activin A inhibitor (e.g., an anti-activin A antibody) includes, for example, an amount of GDF8 inhibitor and / or activin A inhibitor that, when administered to a subject, causes an increase in total lean body mass of at least about 2%-8%, 2.5%-6%, 3%-4%, or at least 2.0%, at least 2.5%, at least 3.0%, or at least 3.5% or more.
[0173] In some embodiments, a "therapeutically effective amount" or "effective amount" of a GDF8 inhibitor (e.g., an anti-GDF8 antibody) and / or an activin A inhibitor (e.g., an anti-activin A antibody) includes, for example, an amount of a GDF8 inhibitor and / or an activin A inhibitor that, when administered to a subject, causes an increase in appendicular lean body mass of at least about 2%-8%, 2.5%-6%, 3%-4%, or at least 2.0%, at least 2.5%, at least 3.0%, or at least 3.5% or more.
[0174] In certain embodiments, this amount also results in an increase in TA or GA muscle mass of at least 2%, 3%, 5%, 10%, 15%, 20%, 25% or more compared to control treated subjects.
[0175] In certain embodiments, a (therapeutically) effective amount of an anti-GDF8 antibody, an anti-activin A antibody, or a bispecific antibody that specifically binds to GDF8 and activin A is from about 0.05 mg to about 600 mg; for example, about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg , about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg or about 600 mg of each antibody. The dosage may vary depending on the age and size of the subject to be administered, the target disease, condition, route of administration, etc. Depending on the severity of the condition, the frequency and duration of treatment may be adjusted.
[0176] The amount of antibody (e.g., an anti-GDF8 antibody, an anti-activin A antibody, or a bispecific antibody that specifically binds GDF8 and activin A) contained within an individual dose can be expressed in terms of milligrams of antibody per kilogram of patient body weight (i.e., mg / kg). For example, the anti-GDF8 antibody, anti-activin A antibody, and / or anti-GDF8 / anti-activin A bispecific antibody in the first, second, or third composition administered according to the methods of the invention can be administered to a patient at a dose of about 0.0001 to about 50 mg / kg of the patient's body weight (e.g., 0.5 mg / kg, 1.0 mg / kg, 1.5 mg / kg, 2.0 mg / kg, 2.5 mg / kg, 3.0 mg / kg, 3.5 mg / kg, 4.0 mg / kg, 4.5 mg / kg, 5.0 mg / kg, 5.5 mg / kg, 6.0 mg / kg, 6.5 mg / kg, 7.0 mg / kg, 7.5 mg / kg, 8.0 mg / kg, 8.5 mg / kg, 9.0 mg / kg, 9.5 mg / kg, 10.0 mg / kg, 10.5 mg / kg, 11.0 mg / kg, 11.5 mg / kg, etc.).
[0177] An effective amount of a GDF8 inhibitor (e.g., an anti-GDF8 antibody) can, in certain embodiments, comprise a dosage regimen selected from the group consisting of at least 0.1 mg / kg to about 10 gm / kg, 1 mg / kg to about 1 gm / kg, and 10 mg / kg to 100 mg / kg. An effective amount of an activin A inhibitor (e.g., an anti-activin A antibody) can, in certain embodiments, comprise a dosage regimen selected from the group consisting of at least 0.1 mg / kg to about 10 gm / kg, 1 mg / kg to about 1 gm / kg, and 10 mg / kg to 100 mg / kg.
[0178] An effective amount of a GDF8 inhibitor (e.g., an anti-GDF8 antibody) can, in additional embodiments, include a dosing regimen selected from the group consisting of a single dose of about 0.01 to about 20 mg / kg body weight, about 0.1 to about 10 mg / kg body weight, and about 0.1 to about 5 mg / kg body weight. An effective amount of an activin A inhibitor (e.g., an anti-activin A antibody) can, in additional embodiments, include a dosing regimen selected from the group consisting of a single dose of about 0.01 to about 20 mg / kg body weight, about 0.1 to about 10 mg / kg body weight, and about 0.1 to about 5 mg / kg body weight. In a specific embodiment, an effective amount of anti-GDF8 antibody is about 2 mg / kg to 10 mg / kg, 4 mg / kg to 8 mg / kg or about 6 mg / kg of the subject's body weight, and an effective amount of anti-activin A antibody is 0.5 mg / kg to 15 mg / kg, 2 mg / kg to 12 mg / kg, about 3 mg / kg or about 10 mg / kg of the subject's body weight.
[0179] The first, second and third compositions administered according to the method of the present invention can, in certain embodiments, contain equal amounts of GDF8 inhibitors (e.g., anti-GDF8 antibodies) and / or activin A inhibitors (e.g., anti-activin A antibodies). Alternatively, the amount of GDF8 inhibitors (e.g., anti-GDF8 antibodies) in the composition can be less than or greater than the amount of activin A inhibitors (e.g., anti-activin A antibodies). The effective amount of GDF8 inhibitors (e.g., anti-GDF8 antibodies) can be lower when combined with activin A inhibitors (e.g., anti-activin A antibodies) than in separate compositions. The effective amount of activin A inhibitors (e.g., anti-activin A antibodies) can be lower when combined with GDF8 inhibitors (e.g., anti-GDF8 antibodies) than in separate compositions. Those skilled in the art can use routine experimentation to determine the appropriate amount of each component in the composition required to produce the desired therapeutic effect.
[0180] Aspects of the Disclosure The present disclosure provides compositions, kits and methods for using GDF8 inhibitors and activin A inhibitors to reduce fat mass (induce fat mass reduction) in subjects.The present disclosure also provides compositions, kits and methods for using GDF8 inhibitors and activin A inhibitors to treat diseases, disorders and / or conditions associated with or characterized by increased fat mass in subjects.In a preferred embodiment, the GDF8 inhibitor is an antibody or its antigen-binding fragment that specifically binds to GDF8.
[0181] Treatment method The present invention includes a method for modifying body composition, for example, a method for inducing a decrease in fat mass in a subject, a method for increasing muscle mass in a subject, and a method for treating a disease or disorder characterized by increased fat mass in a subject, by specifically binding to GDF8 and / or activin A. For example, the present invention includes a method for inducing a decrease in fat mass in a subject, a method for inducing an increase in muscle mass in a subject, and a method for treating a disease or disorder characterized by increased fat mass in a subject, by administering to a subject i) a composition comprising an anti-GDF8 antibody and a composition comprising an anti-activin A antibody, or ii) a composition comprising both an anti-GDF8 antibody and an anti-activin A antibody, or iii) a composition comprising a bispecific antibody comprising a first variable domain comprising a HCVR / LCVR pair that specifically binds to GDF8, and a second variable domain comprising a HCVR / LCVR pair that specifically binds to activin A. In the context of these aspects of the present invention, any of the GDF8 inhibitors and / or activin A inhibitors disclosed or referenced herein can be used.
[0182] In the method comprising administering GDF8 inhibitor and activin A inhibitor to subject, GDF8 inhibitor (for example, anti-GDF8 antibody) and activin A inhibitor (for example, anti-activin A antibody) can be administered to subject at the same or substantially the same time, for example, as a single therapeutic dosage (third composition), or as two separate dosages (first and second composition) that are administered simultaneously or within about 5 minutes or less each other.Alternatively, GDF8 inhibitor and activin A inhibitor (first and second composition) can be administered to subject sequentially, for example, as separate therapeutic dosages that are administered more than about 5 minutes apart each other.
[0183] The reduction in fat mass in a subject of the method of the present invention may be a reduction in total fat mass as measured by DXA (dual energy x-ray absorptiometry).
[0184] In another embodiment, the reduction in fat mass in the subject of the method of the present invention is a reduction in android fat mass (i.e., visceral fat associated with the upper / central area) measured by DXA (dual energy X-ray absorptiometry). In android obesity, the subject stores fat around the subject's abdominal area. Android obesity may also be manifested in other areas of the upper trunk, such as the upper chest (front or back), the nape area of the neck, and even the shoulders. Subjects with android obesity are at greater risk of obesity-related diseases / disorders, such as heart disease and metabolic syndrome. The likelihood of developing gout, arterial-related disease (due to high blood pressure), and many types of cancer are also associated with central-type fat distribution in subjects exhibiting android obesity.
[0185] Body fat assessments vary in accuracy and precision. Common anthropometric measures include body weight, waist circumference, and skinfold measurements using a skinfold thickness gauge. More complex methods include bioelectrical impedance analysis (BIA), BOD POD, and dual energy x-ray absorptiometry (DEXA or DXA). DXA is particularly accurate and effective because it takes into account bone mineral content when estimating body fat and muscle. DEXA scans can assess fat distribution in different regions to determine android / gynoid fat ratio, which is separate from body mass index. DXA can measure total fat mass, total body muscle mass, visceral fat (fat around organs) levels, intramuscular fat (fat between muscles), total bone mineral density, and can even provide a regional analysis. Finally, DXA can accurately assess the distribution of body fat associated with increased insulin resistance.
[0186] Avoiding side effects The present invention includes a method for modifying body composition in a subject, for example, for inducing a loss of fat mass, and a method for treating a disease or disorder characterized by increased fat mass, comprising administering a GDF8 inhibitor and an activin A inhibitor to a subject, without causing adverse side effects associated with administration of a molecule that binds to multiple (e.g., three or more) ActRIIB ligands, as described, for example, in U.S. Pat. No. 8,871,209. For example, a clinical molecule called ACE-031 (Acceleron Pharma, Inc., Cambridge, MA) is a multimer consisting of the extracellular portion of ActRIIB fused to an IgG Fc domain (this molecule is also referred to herein as "ActRIIB-Fc"). ActRIIB-Fc binds to other ActRIIB ligands, such as, for example, activin A, activin B, GDF11, BMP9, BMP10 and TGFβ, along with GDF8, and is known to cause various adverse side effects when administered to human patients. For example, administration of ACE-031 to postmenopausal women in a Phase Ib ascending dose study was shown to cause undesirable hemoglobin increase and FSH level decrease. In addition, a Phase II study of ACE-031 in pediatric patients with muscular dystrophy was discontinued due to adverse effects including nasal and gingival bleeding. Dilated blood vessels are also observed in patients treated with ActRIIB-Fc. The effect of ACE-031 in boys with Duchenne muscular dystrophy (DMD) demonstrated a trend toward lean body mass gain and fat mass loss, but non-muscle-related adverse events contributed to the decision to discontinue the study (Campbell et al., 2017 Muscle Nerve 55:458-464). Specifically inhibiting GDF8 and activin A (e.g., by administering anti-GDF8 and anti-activin A antibodies), but not other ActRIIB ligands such as activin B, GDF11, BMP9, BMP10 and TGFβ, results in increased fat mass loss without causing the adverse side effects associated with non-specific activin binding agents such as ActRIIB-Fc.
[0187] Dosing regimen In certain embodiments of the invention, multiple doses of the compositions of the invention (e.g., compositions comprising GDF8 inhibitors and / or activin A inhibitors, e.g., anti-GDF8 antibodies and / or anti-activin A antibodies, or bispecific antibodies against GDF8 and activin A) can be administered to a subject over a defined time course. The method according to this aspect of the invention comprises sequentially administering multiple doses of the composition(s) of the invention to the subject. As used herein, "sequentially administering" means that each dose of the compositions of the invention is administered to the subject at different time points, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks or months). The invention includes methods comprising sequentially administering to a patient an initial dose of the first and / or second composition; or a third composition; followed by one or more secondary doses of the first and / or second composition; or a third composition; and optionally followed by one or more tertiary doses of the first and / or second composition; or a third composition.
[0188] The terms "initial dose", "secondary dose" and "tertiary dose" refer to the time sequence of administration of the composition of the present invention. Thus, "initial dose" is the dose administered at the beginning of a treatment regimen (also referred to as "baseline dose"); "secondary dose" is the dose administered after the initial dose; and "tertiary dose" is the dose administered after the secondary dose. The initial, secondary and tertiary doses can all contain the same amount of active ingredient(s), for example, anti-GDF8 antibody and / or anti-activin A antibody, but will generally differ from each other in terms of frequency of administration. However, in certain embodiments, the amount of active ingredient(s) contained in the initial, secondary and / or tertiary dose will vary from each other in the course of treatment (e.g., adjusted more or less accordingly).
[0189] In an exemplary embodiment of the invention, each secondary and / or tertiary dose is administered 1-30 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more days) after the immediately preceding dose. The phrase "immediately preceding dose" as used herein refers to a dose(s) of a composition of the invention administered to a subject prior to administration of the immediately succeeding dose in a series of multiple administrations, without any intervening doses.
[0190] The method according to this aspect of the invention can include administering to the patient any number of secondary and / or tertiary doses of the composition of the invention. For example, in certain embodiments, only a single secondary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) secondary doses are administered to the patient. Similarly, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) tertiary doses are administered to the patient.
[0191] In embodiments involving multiple secondary doses, each secondary dose can be administered at the same frequency as the other secondary doses. For example, each secondary dose can be administered to the patient 1-29 days after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose can be administered at the same frequency as the other tertiary doses. For example, each tertiary dose can be administered to the patient 1-60 days after the immediately preceding dose. Alternatively, the frequency at which the secondary and / or tertiary doses are administered to the patient can vary over the course of the treatment regimen. The frequency of administration can also be adjusted by the physician over the course of treatment according to the needs of the individual patient according to clinical trials.
[0192] In one embodiment, the subject is subjected to a preliminary DXA, then receives a composition comprising an anti-GDF8 antibody and an anti-activin A antibody (or a composition comprising an anti-GDF8 antibody and a composition comprising an anti-activin A antibody), and then undergoes a follow-up DXA. If fat mass is not measurably reduced in the follow-up DXA (compared to the preliminary DXA), the subject can again receive the composition(s). The amount and frequency of subsequent dosing may vary based on the results of the follow-up DXA in additional embodiments.
[0193] Combination therapy The method of the present invention, in certain embodiments, comprises administering to a subject one or more additional therapeutic agents that can be advantageously combined with the composition comprising GDF8 inhibitor and / or activin A inhibitor.As used herein, the expression "combined with" means that the additional therapeutic agent(s) is administered before, after or simultaneously with the pharmaceutical composition comprising GDF8 inhibitor and / or activin A inhibitor.The term "combined with" also includes the sequential or concomitant administration of GDF8 inhibitor, activin A inhibitor or both with a second therapeutic agent.The term "therapeutic agent" also means to include specific therapeutic methods.
[0194] Additional therapeutic agents include, for example, another GDF8 antagonist / inhibitor, another activin A antagonist / inhibitor, growth factor inhibitors, immunosuppressants, metabolic inhibitors, enzyme inhibitors, and cytotoxic / cytostatic agents, IL-1 antagonists (including, for example, IL-1 antagonists as described in US 6,927,044), IL-6 antagonists, IL-6R antagonists (including, for example, anti-IL-6R antibodies as described in US 7,582,298), IL-13 antagonists, tumor necrosis factor (TNF) antagonists, IL-8 antagonists, IL-9 antagonists, IL-17 antagonists, IL-5 ..., IL-6R antibodies, IL-6R antibodies, IL-7 antagonists, IL-8R antagonists, IL-9R antagonists, IL-17R antagonists, IL-5R antagonists, IL-8R antagonists, IL-9R antagonists, IL-17R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5R antagonists, IL-5 The therapeutic agent may be an anti-inflammatory drug, such as an anti-inflammatory drug, ...
[0195] In a further embodiment, the invention features a composition, wherein the additional therapeutic agent is (1) a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, such as cerivastatin, atorvastatin, simvastatin, pitavastatin, rosuvastatin, fluvastatin, lovastatin, pravastatin; (2) an inhibitor of cholesterol uptake and / or bile acid reabsorption; (3) niacin, which increases lipoprotein catabolism; (4) an inhibitor of niacin, which reduces low density lipoprotein (LDL) levels and improves high density lipoprotein (HDL) and TG levels; , fibrates or amphipathic carboxylic acids, which reduce the number of non-fatal heart attacks; and (5) activators of LXR transcription factors, which play a role in cholesterol clearance, such as 22-hydroxycholesterol, or fixed combinations, such as ezetimibe plus simvastatin; statins and bile resins (e.g., cholestyramine, colestipol, colesevelam), niacin, plus fixed combinations of statins (e.g., niacin and lovastatin); or combinations with other lipid-lowering agents, such as omega-3 fatty acid ethyl esters (e.g., omacol).
[0196] In yet further embodiments, the second therapeutic agent is selected from inhibitors of other molecules, such as ANGPTL3 (e.g., anti-ANGPTL3 antibodies), ANGPTL4, ANGPTL5, ANGPTL6, apolipoprotein C-III (also referred to as APOC3; see, for example, US8530439, US7750141, US7598227 for inhibitors of APOC3, and boranesorsen, also referred to as ISIS-APOCIIIRx), together with one or more other inhibitors / antagonists of glucagon or inhibitors / antagonists of the glucagon receptor, together with inhibitors of other molecules, such as inhibitors of ANGPTL8 (e.g., anti-ANGPTL8 antibodies), and inhibitors of other molecules, such as proprotein convertase subtilisin / kexin type 9 (PCSK9), which are involved in lipid metabolism, in particular cholesterol and / or triglyceride homeostasis. Inhibitors of these molecules include small molecules, antisense molecules, and antibodies that specifically bind to these molecules and block their activity.
[0197] The additional therapeutic agent, in further embodiments, may be selected from the group consisting of painkillers, anti-inflammatory agents including nonsteroidal anti-inflammatory drugs (NSAIDs) such as Cox-2 inhibitors, etc., if necessary to ameliorate and / or reduce symptoms associated with the underlying condition.
[0198] The additional therapeutic agent(s) may be administered prior to, concurrently with, or following administration of the first and / or second; or third composition(s) described herein. For purposes of this disclosure, such administration regimes may be considered administration of an anti-GDF8 antibody and / or anti-activin A antibody "in combination with" a second therapeutically active component. EXAMPLES
[0199] The following examples are presented to provide those skilled in the art with a complete disclosure and description of how to make and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors consider their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless otherwise specified, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure. EXAMPLES
[0200] Anti-GDF8 alone increased total lean mass by up to 3% in a clinical study: Sarcopenia Phase 2 data A randomized, double-blind, placebo-controlled, interventional phase 2 clinical trial was conducted in patients aged 70 years or older, including men and postmenopausal women with sarcopenia. Patients were treated with subcutaneous anti-GDF8 antibody REGN1033 (H4H1657N2) alone, either 100 mg anti-GDF8 antibody, Q4W sc (n=62); 300 mg anti-GDF8 antibody Q4W sc (n=64) or 300 mg anti-GDF8 antibody Q2W sc (n=59), or placebo (n=65) for 12 weeks. As shown in Figure 1 and as shown in Figure 1 and Table 4, patients showed a significant increase in total lean body mass after 12 weeks when using REGN1033 alone at each of the three doses, compared to placebo.
[0201] [Table 3]
[0202] Effects on strength and function were variable. Anti-GDF8 was generally safe and well tolerated (reactions, if any, were mild). Table 4 shows that patients receiving either the 100 mg or 300 mg dose of REGN1033 demonstrated significantly increased total lean mass as a % change from placebo to week 12 data. The anti-GDF8 antibody REGN1033 alone increased total lean body mass by up to 3% in this study. The 300 mg regimen also resulted in a decrease in total and android fat mass. EXAMPLES
[0203] First-in-human single ascending dose study of anti-GDF8 and anti-activin A combination A randomized, double-blind, placebo-controlled, ascending dose study was initiated to evaluate the tolerability and effects on body composition of a combination of intravenous anti-GDF8 and anti-activin A antibodies versus the individual components.
[0204] The primary objective of this study was to evaluate the safety and tolerability of an anti-activin A antibody (e.g., H4H10446P2 = REGN2477), alone and in combination with an anti-GDF8 antibody (e.g., H4H1657N2 = REGN1033), in healthy postmenopausal women aged 45-70 years.
[0205] Secondary objectives of the study included: assessing the effects of REGN2477 alone, REGN1033 alone, and the combination of REGN2477 + REGN1033 on thigh muscle volume as measured by magnetic resonance imaging (MRI), and assessing the effects of REGN2477 alone, REGN1033 alone, and the combination of REGN2477 + REGN1033 on total and regional body composition as measured by dual-energy X-ray absorptiometry (DXA).
[0206] research design This study was a randomized, double-blind, placebo-controlled, ascending dose study to evaluate the safety, tolerability, and pharmacodynamics of intravenous REGN2477 (anti-activin A) alone and in combination with REGN1033 (anti-GDF8) in healthy postmenopausal women.
[0207] A total of 48 subjects were randomized to one of four sequential ascending REGN2477 IV dose panels: 8 subjects were randomized in a 6:2 ratio to each of the first three panels (Panels A, B, and C), and 24 subjects were randomized in a 1:1:1:1 ratio (6 subjects each) to Panel D. Panel A: 4 subjects receive REGN1033 (6 mg / kg IV) + low dose REGN2477 (1 mg / kg IV) or 2 subjects receive placebo Panel B: 4 subjects REGN1033 (6 mg / kg IV) + intermediate dose REGN2477 (3 mg / kg IV) or 2 subjects placebo Panel C: 4 subjects receive REGN1033 (6 mg / kg IV) + high dose REGN2477 (10 mg / kg IV) or 2 subjects receive placebo Panel D: REGN1033 (6 mg / kg IV) + REGN2477 high dose (10 mg / kg IV) placebo, REGN2477 (10 mg / kg IV) or REGN1033 (6 mg / kg IV)
[0208] Subjects received a single intravenous dose of either or both of the anti-GDF8 antibody REGN1033 and / or the anti-activin A antibody REGN2477. In the primary analysis, the placebo and high-dose combination groups were pooled across the panel, resulting in 12 subjects in placebo and 12 subjects in the high-dose combination, as shown in Figure 2A. The dosing schedule shown in Figure 2A was used in the subsequent studies shown in Figures 2B-17, respectively.
[0209] Subjects participated in a screening period of up to 28 days, followed by a baseline and treatment visit on Day 1, and a 113-day follow-up period.
[0210] Efficacy and safety analysis The Full Analysis Set (FAS) included all randomized subjects; this was based on treatment assigned (as randomized). The FAS was used to analyze efficacy endpoints. The Safety Analysis Set (SAF) included all randomized subjects who received any study drug; this was based on treatment received (as treated). Treatment compliance / administration and all clinical safety variables were analyzed using the SAF.
[0211] Efficacy variables included: thigh muscle tissue volume excluding and including intramuscular adipose tissue and large blood vessels as measured by magnetic resonance imaging (MRI); total lean mass as measured by dual energy x-ray absorptiometry (DXA); appendicular lean mass as measured by DXA (calculated by the aLBM equation); and total fat mass as measured by DXA.
[0212] Subject demographics and baseline characteristics were balanced across treatment groups, as shown in Table 5 below:
[0213] [Table 4]
[0214] statistical methods An analysis of covariance (ANCOVA) model with treatment group as fixed effect and baseline value as continuous covariate was used to analyze percent change and change in efficacy variables from baseline to either week 4 or week 8 in the full analysis set (FAS). Least squares means at week 4 and week 8 by treatment group and corresponding standard errors, confidence intervals, and p-values for treatment comparisons were obtained from this model. Placebo subjects were pooled across panels. Missing efficacy data were not imputed. No adjustment for multiple testing was applied in this study.
[0215] result A total of 48 subjects were randomized, received study drug, and completed the study. One subject in the high-dose REGN2477+REGN1033 group discontinued study drug infusion due to an adverse event of "infusion site swelling."
[0216] efficacy Combined blockade of both activin A and GDF8 increased thigh muscle volume and decreased fat mass at week 8, as shown in Figures 2B and 2C, with the greatest effect observed at the highest dose combination.
[0217] FIG. 2B shows a bar graph depicting percent change in thigh muscle volume by MRI 8 weeks after a single dose in postmenopausal women. Numbers indicate change from placebo. * indicates nominal p<0.05 vs. placebo; ****indicates nominal p<0.0001 vs. placebo. Single dose amounts in mg / kg of either anti-activin A and / or anti-GDF8 antibodies are shown below the bars. Treatment with REGN2477+REGN1033 in the mid and high dose combination resulted in significantly increased thigh muscle volume in a dose-related manner compared to placebo (p<0.05; p<0.0001, respectively). Subjects in the high dose panel showed a maximum % change from baseline of 7.73% at week 8 versus 0.88% with placebo.
[0218] FIG. 2C shows a bar graph depicting the percent change in total fat mass by DXA 8 weeks after a single dose in postmenopausal women. Numbers indicate change from placebo. * indicates nominal p<0.05 vs. placebo; **** indicates nominal p<0.0001 vs. placebo. Single dose amounts in mg / kg of either anti-activin A antibody and / or anti-GDF8 antibody are shown below the bars. Treatment with the high-dose REGN2477+REGN1033 combination resulted in significantly reduced total fat mass (p<0.05) compared to placebo.
[0219] As shown in Figure 3, the anti-activin A antibody REGN2477 in combination with the anti-GDF8 antibody REGN1033 resulted in a dose-dependent increase in thigh muscle volume. Thigh muscle volume results measured by MRI, excluding intermuscular adipose tissue and large blood vessels, are similarly summarized below in Table 6. Treatment with the mid and high dose REGN2477+REGN1033 combination resulted in significantly increased thigh muscle volume (p<0.05) compared to placebo, as shown in Table 6.
[0220] [Table 5]
[0221] As shown in Table 4, treatment with REGN2477+REGN1033 in the mid and high dose combination resulted in significantly increased thigh muscle volume in a dose-related manner compared to placebo.
[0222] Figure 4 shows that increases in thigh muscle volume were consistently observed in individual subjects following treatment with the anti-activin A + anti-GDF8 combination. Within each treatment group, different lines represent different individuals.
[0223] The pattern of effect of the combination of anti-activin A antibody REGN2477 plus anti-GDF8 antibody REGN1033 on appendicular lean mass (the sum of arm and leg lean mass) was similar to that observed in thigh muscle volume, as shown in Figure 5. Appendicular lean mass results measured by DXA are similarly summarized in Table 7. The mid and high dose combinations significantly increased appendicular lean mass compared to placebo, as shown in Table 7.
[0224] [Table 6]
[0225] As shown in FIG. 6, blockade of both activin A and GDF8 resulted in a reduction in total fat mass as assessed by DXA. The high-dose combination of anti-GDF8 antibody REGN1033 and anti-activin A antibody REGN2477 significantly reduced total fat mass by DXA compared to placebo at week 8 ( * p<0.05). Total fat mass results measured by DXA are similarly summarized in Table 8 below.
[0226] [Table 7]
[0227] Blockade of activin A and GDF8 was also found to be associated with a reduction in android fat mass as assessed by DXA, as shown in Figure 7. The high-dose combination of anti-GDF8 antibody REGN1033 and anti-activin A antibody REGN2477 significantly reduced android fat mass by DXA compared to placebo at week 8 ( * p<0.05).
[0228] Further efficacy results are shown in Figures 8-17 and summarized in the table below. REGN2477 + REGN1033 high, medium and low doses are shown in Figure 2A.
[0229] Compared to placebo, the REGN2477+REGN1033 intermediate (p<0.05) and high dose groups (p<0.001) showed significantly increased thigh muscle volume, excluding intramuscular adipose tissue and large blood vessels (Figure 8). Thigh muscle volume increased by 7.73% in the REGN2477+REGN1033 high dose group compared to 0.88% in the placebo group at week 8 (nominal p<0.001). Compared to placebo, the intermediate dose of REGN2477+REGN1033 and REGN1033 alone also significantly increased thigh muscle volume. Increases in thigh muscle volume were consistently observed in individual subjects treated with the combination in a dose-responsive manner (data not shown).
[0230] Compared to placebo, the high dose REGN2477 + REGN1033 group demonstrated significantly increased total lean mass by DXA (p<0.05) (Figure 9).
[0231] Appendicular lean mass (calculated by the aLBM equation) was significantly increased in each of the combination REGN2477+REGN1033 treatment groups compared to placebo (low dose p<0.05, intermediate and high dose groups p<0.001) (FIG. 10). Appendicular lean mass increased 7.15% from baseline in the REGN2477+REGN1033 intermediate dose group compared to 0.76% in the placebo group at week 8. Similarly, appendicular lean mass increased 5.7% from baseline in the REGN2477+REGN1033 high dose group compared to 0.76% in the placebo group.
[0232] Total fat mass was significantly reduced in the high dose REGN2477+REGN1033 treatment group; total fat mass was reduced: 3.92% (high dose group) compared to placebo at 0.5% (nominal p<0.05) (FIG. 11).
[0233] Compared to placebo, thigh muscle volume, including intramuscular adipose tissue and large blood vessels, was significantly increased in the mid- and high-dose REGN2477+REGN1033 groups and the REGN1033 group at weeks 4 and 8, respectively ( FIG. 12 ). Low-dose REGN2477+REGN1033 also showed a significant increase in thigh muscle volume, including intramuscular adipose tissue and large blood vessels, compared to placebo at week 4.
[0234] Appendicular lean mass (arms and legs combined) was significantly increased in each of the combination REGN2477+REGN1033 treatment groups compared to placebo at weeks 4 and 8 (p<0.05) (FIG. 13).
[0235] Android fat mass in the high-dose REGN2477+REGN1033 treatment group was also significantly reduced (FIG. 14). Android fat mass was reduced by 6.6% in the high-dose REGN2477+REGN1033 group compared to no reduction in placebo.
[0236] Thigh intramuscular adipose tissue volume (cm3) was significantly increased in the high-dose REGN2477+REGN1033 group (p<0.05) compared to placebo at week 8 (Figure 15).
[0237] Adipose tissue reduction in the high dose group was observed in the sum of intramuscular and perimuscular adipose tissue (IMAT) (Figure 16), and in the low and intermediate dose groups in subcutaneous adipose tissue (Figure 17). In contrast, thigh intramuscular adipose tissue was increased to 8% in the high dose group compared to placebo by a 4% decrease (Figure 17).
[0238] REGN2477+REGN1033 significantly increased all of the key measures of muscle volume and lean mass compared to placebo at both weeks 4 and 8 in the high-dose group; effects at week 4 were generally less clear than at week 8 (Table 9). A summary of percent changes in key body composition measures at week 8 (full analysis set, LS means and SEs presented) is shown below in Table 9.
[0239] [Table 8]
[0240] In Table 9 above, the change from baseline and the difference from placebo are least squares (LS) means based on an ANCOVA model with baseline as a covariate and treatment as a fixed factor. Standard errors (SE) and p-values were also obtained from the ANCOVA. Nominal p-values are reported.
[0241] Bone mineral density (BMD) mass and bone mineral content (BMC) mass were measured by DXA as shown in Table 10. At the high dose, R2477+R1033 increased bone mineral content as measured by DXA, but did not change total bone mineral density (Table 10).
[0242] The sum of the fat mass in the arms and legs was measured, as shown in Table 10. At the high dose, R2477+R1033 reduced the sum of the fat mass in the arms and legs (p<0.05).
[0243] Data from the primary endpoint analysis are shown in Table 10 below.
[0244] [Table 9] [Table 10] [Table 11] [Table 12] [Table 13] [Table 14] [Table 15] [Table 16] [Table 17]
[0245] Compared to placebo, the R2477+R1033 combination significantly increased thigh muscle volume and total lean mass in the mid and high dose groups (Figures 8 and 9), significantly increased appendicular lean mass in all dose groups (Figure 10), and significantly decreased android fat mass along with total fat mass in the high dose group (Table 10). R2477+R1033 significantly increased all of the major measures of muscle volume and lean mass compared to placebo at both weeks 4 and 8 in the high dose group; effects at week 4 were generally less clear than at week 8 (Table 10). At week 8, the high dose anti-activin A R2477+anti-GDF8 R1033 group showed an increased % change in total bone mineral content from placebo as measured by DXA, but total bone mineral density was unchanged (Table 10).
[0246] safety All treatment-emergent adverse events (TEAEs) were mild to moderate in severity, with the exception of one severe TEAE of "radius fracture" reported by a placebo subject. There were no serious adverse events, no deaths, and no discontinuations due to TEAEs. Headache was the most frequent TEAE in each of the treatment groups, occurring in 58.3% of all study subjects and 50% of placebo subjects. Muscle cramps, nausea, and mouth ulceration were other frequent TEAEs in the REGN2477+REGN1033 group, occurring in more than 25% of subjects in the combination R2477+R1033 group; these TEAEs occurred less frequently than in the placebo group, but did not appear to have any clear dose-response relationship. There were no clear signals of bleeding or diarrhea, adverse events associated with activin receptor blockade. One TEAE of epistaxis (preferred term for nosebleed) occurred in the R2477+R1033 dose group - this resolved after 9 minutes.
[0247] Review of potentially clinically significant values (PCSV) revealed no significant differences between REGN2477+REGN1033 and placebo in labs, vital signs, and ECGs, results that would indicate a negative effect of REGN2477+REGN1033. Within laboratory, vital signs, and ECG categories, there were 0-2 subjects with PCSV in the combined REGN2477+REGN1033 dose group (N of 24); however, the percentage of subjects with PCSV was equal to or less than that found in the placebo group. There were no treatment-emergent PCSVs related to liver function tests.
[0248] conclusion In healthy postmenopausal women, a single intravenous dose of REGN2477+REGN1033 increased thigh muscle volume, total lean mass, and appendicular lean mass. One surprising finding was the uniformity of thigh muscle changes: all individuals exposed to the combination showed increased thigh muscle volume, as shown in Figure 4. In addition, a single intravenous dose of REGN2477+REGN1033 reduced total fat, particularly android fat mass. Treatment with REGN1033 alone increased thigh muscle volume.
[0249] In general, REGN2477, REGN1033 and REGN2477+REGN1033 in this clinical study were considered to have an acceptable safety profile and were well tolerated. There were no serious adverse events.
[0250] The present invention should not be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.
Claims
1. 1. A pharmaceutical composition for use in a method for altering the body composition of a subject having a disease or disorder characterized by increased fat mass, comprising an effective amount of a GDF8 inhibitor, the pharmaceutical composition is administered to the subject in combination with a second composition comprising an effective amount of an activin A inhibitor; The alteration of body composition comprises inducing a loss of fat mass in a subject; the GDF8 inhibitor is an isolated antibody or antigen-binding fragment thereof that specifically binds to GDF8; The antibody or antigen-binding fragment thereof that specifically binds to GDF8 comprises an HCVR comprising SEQ ID NO:360, three HCDRs comprising SEQ ID NO:362, SEQ ID NO:364, and SEQ ID NO:366, and an LCVR comprising SEQ ID NO:368, and three LCDRs comprising SEQ ID NO:370, SEQ ID NO:372, and SEQ ID NO:374; the effective amount of the GDF8 inhibitor is from about 2 mg / kg to about 10 mg / kg of body weight; the activin A inhibitor is an isolated antibody or antigen-binding fragment thereof that specifically binds to activin A; The antibody or antigen-binding fragment thereof that specifically binds to activin A comprises an HCVR comprising SEQ ID NO:553, three HCDRs comprising SEQ ID NO:555, SEQ ID NO:557, and SEQ ID NO:559, and an LCVR comprising SEQ ID NO:537, and three LCDRs comprising SEQ ID NO:539, SEQ ID NO:541, and SEQ ID NO:543; The effective amount of the activin A inhibitor is from about 2 mg / kg to about 12 mg / kg of body weight. The pharmaceutical composition.
2. The method of claim 1 , wherein altering body composition comprises inducing increased muscle mass in a subject.
3. A method for altering the body composition of a subject having a disease or disorder characterized by increased fat mass, comprising administering to said subject an effective amount of a GDF8 inhibitor and an effective amount of an activin A inhibitor. A pharmaceutical composition comprising an anti-inflammatory agent, The method includes administering the composition to a subject; The alteration of body composition comprises inducing a loss of fat mass in a subject; the GDF8 inhibitor is an isolated antibody or antigen-binding fragment thereof that specifically binds to GDF8; The antibody or antigen-binding fragment thereof that specifically binds to GDF8 comprises an HCVR comprising SEQ ID NO:360, three HCDRs comprising SEQ ID NO:362, SEQ ID NO:364, and SEQ ID NO:366, and an LCVR comprising SEQ ID NO:368, and three LCDRs comprising SEQ ID NO:370, SEQ ID NO:372, and SEQ ID NO:374; the effective amount of the anti-GDF8 inhibitor is from about 2 mg / kg to about 10 mg / kg of body weight; The activin A inhibitor is an isolated antibody or antigen-binding fragment thereof that specifically binds to activin A, The antibody or antigen-binding fragment thereof that specifically binds to activin A comprises an HCVR comprising SEQ ID NO:553, three HCDRs comprising SEQ ID NO:555, SEQ ID NO:557, and SEQ ID NO:559, and an LCVR comprising SEQ ID NO:537, and three LCDRs comprising SEQ ID NO:539, SEQ ID NO:541, and SEQ ID NO:543; The effective amount of the activin A inhibitor is from about 2 mg / kg to about 12 mg / kg of body weight. The pharmaceutical composition.
4. The method of claim 3 , wherein altering body composition comprises inducing increased muscle mass in a subject.
5. The pharmaceutical composition of any one of claims 1 to 4, wherein the effective amount of the GDF8 inhibitor is about 6 mg / kg of the subject's body weight.
6. The pharmaceutical composition of any one of claims 1 to 5, wherein the effective amount of the activin A inhibitor is about 3 mg / kg or about 10 mg / kg of the subject's body weight.
7. The pharmaceutical composition of any one of claims 1 to 4, wherein the composition is formulated for intravenous, subcutaneous or oral administration.
8. 3. The pharmaceutical composition of claim 1 or 2, wherein the second composition is formulated for intravenous, subcutaneous or oral administration.
9. 3. The pharmaceutical composition of claim 1 or 2, wherein the pharmaceutical composition and the second composition are combined into a third composition prior to administration.
10. 10. The pharmaceutical composition of claim 9, wherein the third composition is formulated for intravenous, subcutaneous or oral administration.
11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the total fat mass and / or android fat mass in the subject is measured before administration.
12. 12. The pharmaceutical composition of claim 11, wherein the composition is administered until total fat mass and / or android fat mass in the subject is measured after administration and the subject achieves a reduction in total fat mass and / or android fat mass of at least about 2% to 8%, at least about 2.5% to 6%, at least about 3% to 4%, or at least about 3.5%.
13. 13. The pharmaceutical composition of any one of claims 1 to 12, wherein the activin A inhibitor is in an amount selected from the group consisting of between 100% and 200% of the amount of the GDF8 inhibitor, between 100% and 250% of the amount of the GDF8 inhibitor, between 100% and 300% of the amount of the GDF8 inhibitor, and between 100% and 400% by weight of the amount of the GDF8 inhibitor.
14. The pharmaceutical composition of claim 13, wherein the amount of the activin A inhibitor is about 1.5 to 2.0 times greater by weight than the amount of the GDF8 inhibitor.
15. The pharmaceutical composition according to any one of claims 1 to 14, wherein the reduction in fat mass in a subject is a reduction in total fat mass as measured by DXA (dual energy X-ray absorptiometry).
16. The pharmaceutical composition according to any one of claims 1 to 15, wherein the reduction in fat mass in a subject is a reduction in android fat mass as measured by DXA (dual energy X-ray absorptiometry).
17. The pharmaceutical composition of any one of claims 1 to 16, wherein the subject experiences an increase in muscle mass following administration.
18. The pharmaceutical composition of any one of claims 1 to 17, wherein the subject is free of a muscle wasting condition or disease.
19. 1. A pharmaceutical composition comprising a GDF8 inhibitor for use in a method for treating a disease or disorder characterized by increased fat mass, comprising: The pharmaceutical composition is administered in combination with an activin A inhibitor to a subject having a disease or disorder characterized by increased fat mass; the GDF8 inhibitor is an isolated antibody or antigen-binding fragment thereof that specifically binds to GDF8; The antibody or antigen-binding fragment thereof that specifically binds to GDF8 comprises an HCVR comprising SEQ ID NO:360, three HCDRs comprising SEQ ID NO:362, SEQ ID NO:364, and SEQ ID NO:366, and an LCVR comprising SEQ ID NO:368, and three LCDRs comprising SEQ ID NO:370, SEQ ID NO:372, and SEQ ID NO:374; the effective amount of the GDF8 inhibitor is from about 2 mg / kg to about 10 mg / kg of body weight; The activin A inhibitor is an isolated antibody or antigen-binding fragment thereof that specifically binds to activin A, The antibody or antigen-binding fragment thereof that specifically binds to activin A comprises an HCVR comprising SEQ ID NO:553, three HCDRs comprising SEQ ID NO:555, SEQ ID NO:557, and SEQ ID NO:559, and an LCVR comprising SEQ ID NO:537, and three LCDRs comprising SEQ ID NO:539, SEQ ID NO:541, and SEQ ID NO:543; The effective amount of the activin A inhibitor is from about 2 mg / kg to about 12 mg / kg of body weight. The pharmaceutical composition.
20. 1. A pharmaceutical composition comprising an activin A inhibitor for use in a method for treating a disease or disorder characterized by increased fat mass, comprising: The pharmaceutical composition is administered in combination with a GDF8 inhibitor to a subject having a disease or disorder characterized by increased fat mass; the activin A inhibitor is an isolated antibody or antigen-binding fragment thereof that specifically binds to activin A; The antibody or antigen-binding fragment thereof that specifically binds to activin A includes an HCVR comprising SEQ ID NO:553, three HVRs comprising SEQ ID NO:555, SEQ ID NO:557, and SEQ ID NO:
559. CDRs, and an LCVR comprising SEQ ID NO:537, three LCDRs comprising SEQ ID NO:539, SEQ ID NO:541 and SEQ ID NO:543; the effective amount of the activin A inhibitor is from about 2 mg / kg to about 12 mg / kg of body weight; the GDF8 inhibitor is an isolated antibody or antigen-binding fragment thereof that specifically binds to GDF8; The antibody or antigen-binding fragment thereof that specifically binds to GDF8 comprises an HCVR comprising SEQ ID NO:360, three HCDRs comprising SEQ ID NO:362, SEQ ID NO:364, and SEQ ID NO:366, and an LCVR comprising SEQ ID NO:368, and three LCDRs comprising SEQ ID NO:370, SEQ ID NO:372, and SEQ ID NO:374; The pharmaceutical composition, wherein the effective amount of the GDF8 inhibitor is from about 2 mg / kg to about 10 mg / kg of body weight.
Citation Information
Patent Citations
Compositions and methods for increasing muscle mass and strength by specifically antagonizing GDF8 and / or activin A
JP2014534239A
Anti-Activin A Antibody and Its Use
JP2016528232A
Antibodies to myostatin
US20060263354A1
Anti-myostatin antibodies
US20070178095A1
Anti-Myostatin Antibodies
US20080299126A1
